Breast Cancer

Overview

Literature Analysis

Mouse over the terms for more detail; many indicate links which you can click for dedicated pages about the topic.

Tag cloud generated 29 August, 2019 using data from PubMed, MeSH and CancerIndex

Mutated Genes and Abnormal Protein Expression (1228)

How to use this data tableClicking on the Gene or Topic will take you to a separate more detailed page. Sort this list by clicking on a column heading e.g. 'Gene' or 'Topic'.

GeneLocationAliasesNotesTopicPapers
BRCA2 13q13.1 FAD, FACD, FAD1, GLM3, BRCC2, FANCD, PNCA2, FANCD1, XRCC11, BROVCA2 -BRCA2 and Breast Cancer
-Prophylactic Treatments for Women with BRCA1/BRAC2 mutations
-BRCA2 and Breast Cancer During Pregnancy
-BRCA2 and Outcome in Breast Cancer
 3000
BRCA1 17q21.31 IRIS, PSCP, BRCAI, BRCC1, FANCS, PNCA4, RNF53, BROVCA1, PPP1R53 Germline
 -185delAG mutation (c.68_69delAG) in BRCA1
-Prophylactic Treatments for Women with BRCA1/BRAC2 mutations
-BRCA1 mutations in Breast Cancer
 3000
MKI67 10q26.2 KIA, MIB-, MIB-1, PPP1R105 -MKI67 and Breast Cancer
 2126
TP53 17p13.1 P53, BCC7, LFS1, TRP53 -TP53 mutations in Breast Cancer
 1606
BCR 22q11.23 ALL, CML, PHL, BCR1, D22S11, D22S662 -BCR and Breast Cancer
 1208
ERBB2 17q12 NEU, NGL, HER2, TKR1, CD340, HER-2, MLN 19, HER-2/neu Gene Amplification
 -HER2 and Breast Cancer
 816
MUC1 1q22 EMA, MCD, PEM, PUM, KL-6, MAM6, MCKD, PEMT, CD227, H23AG, MCKD1, MUC-1, ADMCKD, ADMCKD1, CA 15-3, MUC-1/X, MUC1/ZD, MUC-1/SEC Prognostic
 -MUC1 Expression in Breast Cancer
 558
NODAL 10q22.1 HTX5 -NODAL and Breast Cancer
 543
CYP19A1 15q21.2 ARO, ARO1, CPV1, CYAR, CYP19, CYPXIX, P-450AROM -CYP19A1 and Breast Cancer
 540
PTEN 10q23.31 BZS, DEC, CWS1, GLM2, MHAM, TEP1, MMAC1, PTEN1, 10q23del -PTEN and Breast Cancer
 536
AR Xq12 KD, AIS, AR8, TFM, DHTR, SBMA, HYSP1, NR3C4, SMAX1, HUMARA -AR and Breast Cancer
 505
MTOR 1p36.22 SKS, FRAP, FRAP1, FRAP2, RAFT1, RAPT1 -MTOR and Breast Cancer
 454
SRC 20q11.23 ASV, SRC1, THC6, c-SRC, p60-Src -SRC and Breast Cancer
 450
AKT1 14q32.33 AKT, PKB, RAC, CWS6, PRKBA, PKB-ALPHA, RAC-ALPHA -AKT1 and Breast Cancer
 403
CHEK2 22q12.1 CDS1, CHK2, LFS2, RAD53, hCds1, HuCds1, PP1425 -CHEK2 and Breast Cancer
 373
PROC 2q13-q14 PC, APC, PROC1, THPH3, THPH4 -PROC and Breast Cancer
 342
PTGS2 1q31.1 COX2, COX-2, PHS-2, PGG/HS, PGHS-2, hCox-2, GRIPGHS -PTGS2 (COX2) and Breast Cancer
-COX2 Inhibitors for Breast Cancer
 223
CTNNB1 3p22.1 CTNNB, MRD19, armadillo -CTNNB1 and Breast Cancer
 334
BIRC5 17q25.3 API4, EPR-1 -BIRC5 and Breast Cancer
 329
ESR1 6q25.1-q25.2 ER, ESR, Era, ESRA, ESTRR, NR3A1 -ESR1 and Breast Cancer
 326
PIK3CA 3q26.32 MCM, CWS5, MCAP, PI3K, CLOVE, MCMTC, PI3K-alpha, p110-alpha -PIK3CA and Breast Cancer
 324
CD44 11p13 IN, LHR, MC56, MDU2, MDU3, MIC4, Pgp1, CDW44, CSPG8, HCELL, HUTCH-I, ECMR-III -CD44 and Breast Cancer
 320
KITLG 12q22 SF, MGF, SCF, FPH2, FPHH, KL-1, Kitl, SHEP7 -KITLG and Breast Cancer
 304
CDKN1A 6p21.2 P21, CIP1, SDI1, WAF1, CAP20, CDKN1, MDA-6, p21CIP1 -CDKN1A and Breast Cancer
 304
TNF 6p21.33 DIF, TNFA, TNFSF2, TNLG1F, TNF-alpha -TNF and Breast Cancer
 287
BAX 19q13.33 BCL2L4 -BAX and Breast Cancer
 274
MET 7q31.2 HGFR, AUTS9, RCCP2, c-Met, DFNB97 -C-MET and Triple Negative Breast Cancer
-C-MET and Breast Cancer
-Proto-Oncogene Proteins c-met and Triple Negative Breast Cancer
 236
CDKN2A 9p21.3 ARF, MLM, P14, P16, P19, CMM2, INK4, MTS1, TP16, CDK4I, CDKN2, INK4A, MTS-1, P14ARF, P19ARF, P16INK4, P16INK4A, P16-INK4A -CDKN2A and Breast Cancer
 271
CCND1 11q13.3 BCL1, PRAD1, U21B31, D11S287E -CCND1 and Breast Cancer
 268
CYP2D6 22q13.2 CPD6, CYP2D, CYP2DL1, CYPIID6, P450C2D, P450DB1, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2, P450-DB1 -CYP2D6 and Breast Cancer
 259
MYC 8q24.21 MRTL, MYCC, c-Myc, bHLHe39 -MYC and Breast Cancer
 248
TOP1 20q12 TOPI -TOP1 and Breast Cancer
 241
RAD51 15q15.1 RECA, BRCC5, FANCR, MRMV2, HRAD51, RAD51A, HsRad51, HsT16930 -RAD51 and Breast Cancer
 239
ATM 11q22.3 AT1, ATA, ATC, ATD, ATE, ATDC, TEL1, TELO1 -ATM and Breast Cancer
 232
CDH1 16q22.1 UVO, CDHE, ECAD, LCAM, Arc-1, CD324 -CDH1 and Breast Cancer
 219
GSTP1 11q13.2 PI, DFN7, GST3, GSTP, FAEES3, HEL-S-22 -GSTP1 and Breast Cancer
 214
MDM2 12q15 HDMX, hdm2, ACTFS -MDM2 and Breast Cancer
 205
STAT3 17q21.2 APRF, HIES, ADMIO, ADMIO1 -STAT3 and Breast Cancer
 197
MMP2 16q12.2 CLG4, MONA, CLG4A, MMP-2, TBE-1, MMP-II -MMP2 and Breast Cancer
 196
HIF1A 14q23.2 HIF1, MOP1, PASD8, HIF-1A, bHLHe78, HIF-1alpha, HIF1-ALPHA, HIF-1-alpha -HIF1A and Breast Cancer
 195
FGFR2 10q26.13 BEK, JWS, BBDS, CEK3, CFD1, ECT1, KGFR, TK14, TK25, BFR-1, CD332, K-SAM -FGFR2 and Breast Cancer
 186
TIMP1 Xp11.3 EPA, EPO, HCI, CLGI, TIMP, TIMP-1 -TIMP1 and Breast Cancer
 185
CYP1A1 15q24.1 AHH, AHRR, CP11, CYP1, CYPIA1, P1-450, P450-C, P450DX -CYP1A1 and Breast Cancer
 183
CDKN1B 12p13.1 KIP1, MEN4, CDKN4, MEN1B, P27KIP1 Prognostic
 -CDKN1B and Breast Cancer
 181
VEGFA 6p21.1 VPF, VEGF, MVCD1 -VEGFA and Breast Cancer
 176
KLK3 19q13.33 APS, PSA, hK3, KLK2A1 -PSA expression in Breast Cancer
 174
GSTM1 1p13.3 MU, H-B, GST1, GTH4, GTM1, MU-1, GSTM1-1, GSTM1a-1a, GSTM1b-1b -GSTM1 and Breast Cancer
 171
PARP1 1q42.12 PARP, PPOL, ADPRT, ARTD1, ADPRT1, PARP-1, ADPRT 1, pADPRT-1 -PARP1 and Breast Cancer
 169
CD24 6q21 CD24A -CD24 and Breast Cancer
 168
BCL2 18q21.33 Bcl-2, PPP1R50 -BCL2 and Breast Cancer
 165
FOS 14q24.3 p55, AP-1, C-FOS -FOS and Breast Cancer
 163
TFF1 21q22.3 pS2, BCEI, HPS2, HP1.A, pNR-2, D21S21 -TFF1 and Breast Cancer
 162
NOTCH1 9q34.3 hN1, AOS5, TAN1, AOVD1 -NOTCH1 and Breast Cancer
 153
IGF1R 15q26.3 IGFR, CD221, IGFIR, JTK13 -IGF1R and Breast Cancer
 153
TGFB1 19q13.2 CED, LAP, DPD1, TGFB, TGFbeta -TGFB1 and Breast Cancer
 145
ABCB1 7q21.12 CLCS, MDR1, P-GP, PGY1, ABC20, CD243, GP170 -ABCB1 and Breast Cancer
 145
PCNA 20p12.3 ATLD2 -PCNA and Breast Cancer
 142
COMT 22q11.21 HEL-S-98n -COMT and Breast Cancer
 133
TOP2A 17q21.2 TOP2, TP2A -TOP2A and Breast Cancer
 130
CXCR4 2q21 FB22, HM89, LAP3, LCR1, NPYR, WHIM, CD184, LAP-3, LESTR, NPY3R, NPYRL, WHIMS, HSY3RR, NPYY3R, D2S201E -CXCR4 and Breast Cancer
 129
MIR21 17q23.1 MIRN21, miR-21, miRNA21, hsa-mir-21 -MicroRNA miR-21 and Breast Cancer
 128
CAMP 3p21.31 LL37, CAP18, CRAMP, HSD26, CAP-18, FALL39, FALL-39 -CAMP and Breast Cancer
 128
XRCC1 19q13.31 RCC -XRCC1 and Breast Cancer
 127
CYP1B1 2p22.2 CP1B, GLC3A, CYPIB1, P4501B1 -CYP1B1 and Breast Cancer
 126
BLID 11q24.1 BRCC2 -BLID and Breast Cancer
 124
SNAI1 20q13.13 SNA, SNAH, SNAIL, SLUGH2, SNAIL1, dJ710H13.1 -SNAI1 and Breast Cancer
 121
CISH 3p21.2 CIS, G18, SOCS, CIS-1, BACTS2 -CISH and Breast Cancer
 120
CASP8 2q33-q34 CAP4, MACH, MCH5, FLICE, ALPS2B, Casp-8 -CASP8 and Breast Cancer
 119
GSTT1 22q11.23 -GSTT1 Polymorphisms and Breast Cancer
 117
CXCL12 10q11.21 IRH, PBSF, SDF1, TLSF, TPAR1, SCYB12 -CXCL12 and Breast Cancer
 113
CDK4 12q14.1 CMM3, PSK-J3 -CDK4 and Breast Cancer
 111
E2F1 20q11.22 RBP3, E2F-1, RBAP1, RBBP3 -E2F1 and Breast Cancer
 109
TWIST1 7p21.1 CRS, CSO, SCS, ACS3, CRS1, BPES2, BPES3, TWIST, bHLHa38 -TWIST1 and Breast Cancer
 108
ABCG2 4q22.1 MRX, MXR, ABCP, BCRP, BMDP, MXR1, ABC15, BCRP1, CD338, GOUT1, MXR-1, CDw338, UAQTL1, EST157481 -ABCG2 and Breast Cancer
 108
BARD1 2q35 -BARD1 and Breast Cancer
 106
GATA3 10p14 HDR, HDRS -GATA3 and Breast Cancer
 104
RASSF1 3p21.31 123F2, RDA32, NORE2A, RASSF1A, REH3P21 -RASSF1 and Breast Cancer
 103
FOXA1 14q21.1 HNF3A, TCF3A -FOXA1 and Breast Cancer
 99
BAD 11q13.1 BBC2, BCL2L8 -BAD and Breast Cancer
 99
TGFBR1 9q22.33 AAT5, ALK5, ESS1, LDS1, MSSE, SKR4, ALK-5, LDS1A, LDS2A, TGFR-1, ACVRLK4, tbetaR-I -TGFBR1 and Breast Cancer
 98
BCL2L1 20q11.21 BCLX, BCL2L, Bcl-X, PPP1R52, BCL-XL/S -BCL2L1 and Breast Cancer
 96
CYP17A1 10q24.32 CPT7, CYP17, S17AH, P450C17 -CYP17A1 and Breast Cancer
 95
SMAD3 15q22.33 LDS3, LDS1C, MADH3, JV15-2, HSPC193, HsT17436 -SMAD3 and Breast Cancer
 94
TERT 5p15.33 TP2, TRT, CMM9, EST2, TCS1, hTRT, DKCA2, DKCB4, hEST2, PFBMFT1 -TERT and Breast Cancer
 92
AURKA 20q13.2 AIK, ARK1, AURA, BTAK, STK6, STK7, STK15, PPP1R47 -AURKA and Breast Cancer
 88
ETS1 11q24.3 p54, ETS-1, EWSR2, c-ets-1 -ETS1 and Breast Cancer
 87
IL6 7p15.3 CDF, HGF, HSF, BSF2, IL-6, BSF-2, IFNB2, IFN-beta-2 -IL6 and Breast Cancer
 86
CDK2 12q13 CDKN2, p33(CDK2) -CDK2 and Breast Cancer
 86
CYP3A4 7q22.1 HLP, CP33, CP34, CYP3A, NF-25, CYP3A3, P450C3, CYPIIIA3, CYPIIIA4, P450PCN1 -CYP3A4 and Breast Cancer
 83
RHOC 1p13.2 H9, ARH9, ARHC, RHOH9 -RHOC and Breast Cancer
 83
FGFR1 8p11.23 CEK, FLG, HH2, OGD, ECCL, FLT2, KAL2, BFGFR, CD331, FGFBR, FLT-2, HBGFR, N-SAM, FGFR-1, HRTFDS, bFGF-R-1 -FGFR1 and Breast Cancer
 83
JUN 1p32.1 AP1, p39, AP-1, cJUN, c-Jun -c-Jun and Breast Cancer
 82
CCNB1 5q13.2 CCNB -CCNB1 and Breast Cancer
 82
ZEB1 10p11.22 BZP, TCF8, AREB6, FECD6, NIL2A, PPCD3, ZFHEP, ZFHX1A, DELTAEF1 -ZEB1 and Breast Cancer
 81
SULT1A1 16p11.2 PST, STP, STP1, P-PST, ST1A1, ST1A3, TSPST1, HAST1/HAST2 -SULT1A1 and Breast Cancer
 81
NME1 17q21.33 NB, AWD, NBS, GAAD, NDKA, NM23, NDPKA, NDPK-A, NM23-H1 -NME1 and Breast Cancer
 81
XRCC3 14q32.33 CMM6 -XRCC3 and Breast Cancer
 80
IGFBP3 7p12.3 IBP3, BP-53 -IGFBP3 and Breast Cancer
 79
AKT2 19q13.2 PKBB, PRKBB, HIHGHH, PKBBETA, RAC-BETA -AKT2 and Breast Cancer
 77
FH 1q43 MCL, FMRD, HsFH, LRCC, HLRCC, MCUL1 -FH and Breast Cancer
 77
CDC42 1p36.12 TKS, G25K, CDC42Hs -CDC42 and Breast Cancer
 76
ERBB3 12q13 HER3, LCCS2, ErbB-3, c-erbB3, erbB3-S, MDA-BF-1, c-erbB-3, p180-ErbB3, p45-sErbB3, p85-sErbB3 -ERBB3 and Breast Cancer
 76
FLT1 13q12.3 FLT, FLT-1, VEGFR1, VEGFR-1 -FLT1 and Breast Cancer
 74
RHOA 3p21.31 ARHA, ARH12, RHO12, RHOH12 -RHOA and Breast Cancer
 74
ACHE 7q22.1 YT, ACEE, ARACHE, N-ACHE -ACHE and Breast Cancer
 74
EZH2 7q36.1 WVS, ENX1, EZH1, KMT6, WVS2, ENX-1, EZH2b, KMT6A -EZH2 and Breast Cancer
 72
CYP3A5 7q22.1 CP35, PCN3, CYPIIIA5, P450PCN3 -CYP3A5 and Breast Cancer
 72
CEACAM5 19q13.2 CEA, CD66e -CEACAM5 and Breast Cancer
 71
RB1 13q14.2 RB, pRb, OSRC, pp110, p105-Rb, PPP1R130 -RB1 mutations in Breast Cancer
 70
BRAP 12q24.12 IMP, BRAP2, RNF52 -BRAP and Breast Cancer
 70
FGF2 4q28.1 BFGF, FGFB, FGF-2, HBGF-2 -FGF2 and Breast Cancer
 69
SCGB2A2 11q12.3 MGB1, UGB2 -SCGB2A2 and Breast Cancer
 69
HRAS 11p15.5 CTLO, HAMSV, HRAS1, RASH1, p21ras, C-H-RAS, H-RASIDX, C-BAS/HAS, C-HA-RAS1 -HRAS and Breast Cancer
 69
TGFA 2p13 TFGA -TGFA and Breast Cancer
 69
RELA 11q13.1 p65, NFKB3 -RELA and Breast Cancer
 69
NCOA3 20q13.12 ACTR, AIB1, RAC3, SRC3, pCIP, AIB-1, CTG26, SRC-3, CAGH16, KAT13B, TNRC14, TNRC16, TRAM-1, bHLHe42 -NCOA3 and Breast Cancer
 68
DNMT1 19p13.2 AIM, DNMT, MCMT, CXXC9, HSN1E, ADCADN, m.HsaI -DNMT1 and Breast Cancer
 68
NBN 8q21.3 ATV, NBS, P95, NBS1, AT-V1, AT-V2 -NBN and Breast Cancer
 68
HDAC1 1p35.2-p35.1 HD1, RPD3, KDAC1, GON-10, RPD3L1 -HDAC1 and Breast Cancer
 67
NAT2 8p22 AAC2, PNAT, NAT-2 -NAT2 and Breast Cancer
 66
FOXP3 Xp11.23 JM2, AIID, IPEX, PIDX, XPID, DIETER -FOXP3 and Breast Cancer
 66
MYB 6q23.3 efg, Cmyb, c-myb, c-myb_CDS -MYB and Breast Cancer
 66
RAC1 7p22.1 MIG5, Rac-1, TC-25, p21-Rac1 -RAC1 and Breast Cancer
 66
ITGB1 10p11.22 CD29, FNRB, MDF2, VLAB, GPIIA, MSK12, VLA-BETA -ITGB1 (CD29) and Breast Cancer
 65
FGF3 11q13.3 INT2, HBGF-3 -FGF3 and Breast Cancer
 65
RAD51C 17q22 FANCO, R51H3, BROVCA3, RAD51L2 -RAD51C and Breast Cancer
 63
STK11 19p13.3 PJS, LKB1, hLKB1 -STK11 and Breast Cancer
 61
TTPA 8q12.3 ATTP, AVED, TTP1, alphaTTP -TTPA and Breast Cancer
 61
IGF2 11p15.5 GRDF, IGF-II, PP9974, C11orf43 -IGF2 and Breast Cancer
 61
MAP3K1 5q11.2 MEKK, MEKK1, SRXY6, MEKK 1, MAPKKK1 -MAP3K1 and Breast Cancer
 61
RAD50 5q31.1 NBSLD, RAD502, hRad50 -RAD50 and Breast Cancer
 60
H2AFX 11q23.3 H2AX, H2A.X, H2A/X -H2AFX and Breast Cancer
 60
CHIA 1p13.2 CHIT2, AMCASE, TSA1902 -CHIA and Breast Cancer
 60
IGF2R 6q25.3 MPR1, MPRI, CD222, CIMPR, M6P-R, MPR300, CI-M6PR, MPR 300, M6P/IGF2R -IGF2R and Breast Cancer
 59
HGF 7q21.11 SF, HGFB, HPTA, F-TCF, DFNB39 -HGF and Breast Cancer
 59
TFAP2C 20q13.31 ERF1, TFAP2G, hAP-2g, AP2-GAMMA -TFAP2C and Breast Cancer
 58
ALDH1A1 9q21.13 ALDC, ALDH1, HEL-9, HEL12, PUMB1, ALDH11, RALDH1, ALDH-E1, HEL-S-53e -ALDH1A1 and Breast Cancer
 58
ERCC2 19q13.32 EM9, TTD, XPD, TTD1, COFS2, TFIIH -ERCC2 and Breast Cancer
 57
SMAD4 18q21.2 JIP, DPC4, MADH4, MYHRS -SMAD4 and Breast Cancer
 55
TFAP2A 6p24.3 AP-2, BOFS, AP2TF, TFAP2, AP-2alpha -TFAP2A Expression in Breast Cancer
 54
HSD17B2 16q23.3 HSD17, SDR9C2, EDH17B2 -HSD17B2 and Breast Cancer
 53
ABCC1 16p13.11 MRP, ABCC, GS-X, MRP1, ABC29 -ABCC1 (MRP1) and Breast Cancer
 52
TNFRSF11A 18q21.33 FEO, OFE, ODFR, OSTS, PDB2, RANK, CD265, OPTB7, TRANCER, LOH18CR1 -TNFRSF11A and Breast Cancer
 52
LSP1 11p15.5 WP34, pp52 -LSP1 and Breast Cancer
 52
WNT1 12q13.12 INT1, OI15, BMND16 -WNT1 and Breast Cancer
 51
SOX2 3q26.33 ANOP3, MCOPS3 -SOX2 and Breast Cancer
 51
PRC1 15q26.1 ASE1 -PRC1 and Breast Cancer
 51
GAPDH 12p13.31 G3PD, GAPD, HEL-S-162eP -GAPDH and Breast Cancer
 50
CAV1 7q31.2 CGL3, PPH3, BSCL3, LCCNS, VIP21, MSTP085 -CAV1 and Breast Cancer
 50
NQO1 16q22.1 DTD, QR1, DHQU, DIA4, NMOR1, NMORI -NQO1 and Breast Cancer
 49
VEGFC 4q34.3 VRP, Flt4-L, LMPH1D -VEGFC and Breast Cancer
 49
TGFBR2 3p24.1 AAT3, FAA3, LDS2, MFS2, RIIC, LDS1B, LDS2B, TAAD2, TGFR-2, TGFbeta-RII -TGFBR2 and Breast Cancer
 49
SHBG 17p13.1 ABP, SBP, TEBG -SHBG and Breast Cancer
 48
TOX3 16q12.1 CAGF9, TNRC9 -TOX3 and Breast Cancer
 48
KRT5 12q13.13 K5, CK5, DDD, DDD1, EBS2, KRT5A -KRT5 and Breast Cancer
 47
GPER1 7p22.3 mER, CEPR, GPER, DRY12, FEG-1, GPR30, LERGU, LyGPR, CMKRL2, LERGU2, GPCR-Br -GPER and Breast Cancer
 46
SOD2 6q25.3 IPOB, IPO-B, MNSOD, MVCD6, Mn-SOD -SOD2 and Breast Cancer
 46
MMP1 11q22.2 CLG, CLGN -MMP1 and Breast Cancer
 45
PDGFB 22q13.1 SIS, SSV, IBGC5, PDGF2, c-sis, PDGF-2 -PDGFB and Breast Cancer
 45
EPCAM 2p21 ESA, KSA, M4S1, MK-1, DIAR5, EGP-2, EGP40, KS1/4, MIC18, TROP1, EGP314, HNPCC8, TACSTD1 -EPCAM and Breast Cancer
 45
GRB7 17q12 -GRB7 and Breast Cancer
 45
CXCL1 4q13.3 FSP, GRO1, GROa, MGSA, NAP-3, SCYB1, MGSA-a -CXCL1 and Breast Cancer
 44
S100A4 1q21.3 42A, 18A2, CAPL, FSP1, MTS1, P9KA, PEL98 -S100A4 and Breast Cancer
 44
BRMS1 11q13.2 -BRMS1 and Breast Cancer
 44
CCND2 12p13.32 MPPH3, KIAK0002 -CCND2 and Breast Cancer
 44
CYP1A2 15q24.1 CP12, P3-450, P450(PA) -CYP1A2 and Breast Cancer
 43
NTRK3 15q25.3 TRKC, GP145-TrkC, gp145(trkC) Translocation
 -NTRK3 and Breast Cancer
-t(12;15)(p13;q25) ETV6-NTRK3 in Breast Cancer
 37
DNMT3B 20q11.21 ICF, ICF1, M.HsaIIIB -DNMT3B and Breast Cancer
 43
CCK 3p22.1 -CCK and Breast Cancer
 42
PTK2 8q24.3 FAK, FADK, FAK1, FRNK, PPP1R71, p125FAK, pp125FAK -PTK2 and Breast Cancer
 42
IGF1 12q23.2 IGFI, IGF-I, IGF1A -IGF1 and Breast Cancer
 42
XIAP Xq25 API3, ILP1, MIHA, XLP2, BIRC4, IAP-3, hIAP3, hIAP-3 -XIAP and Breast Cancer
 42
FOXO3 6q21 FOXO2, AF6q21, FKHRL1, FOXO3A, FKHRL1P2 -FOXO3 and Breast Cancer
 41
SMAD2 18q21.1 JV18, MADH2, MADR2, JV18-1, hMAD-2, hSMAD2 -SMAD2 and Breast Cancer
 41
NOTCH2 1p12 hN2, AGS2, HJCYS -NOTCH2 and Breast Cancer
 41
OLAH 10p13 SAST, AURA1, THEDC1 -OLAH and Breast Cancer
 41
ERBB4 2q33.3-q34 HER4, ALS19, p180erbB4 -ERBB4 and Breast Cancer
 40
CYP2C19 10q23.33 CPCJ, CYP2C, P450C2C, CYPIIC17, CYPIIC19, P450IIC19 -CYP2C19 and Breast Cancer
 40
MDM4 1q32.1 HDMX, MDMX, MRP1 -MDM4 and Breast Cancer
 40
SFRP1 8p11.21 FRP, FRP1, FrzA, FRP-1, SARP2 -SFRP1 and Breast Cancer
 40
STAT1 2q32.2 CANDF7, IMD31A, IMD31B, IMD31C, ISGF-3, STAT91 -STAT1 and Breast Cancer
 39
BACH1 21q21.3 BACH-1, BTBD24 -BACH1 and Breast Cancer
 39
STAR 8p11.23 STARD1 -STAR and Breast Cancer
 39
CCNE1 19q12 CCNE, pCCNE1 -CCNE1 and Breast Cancer
 39
EIF4E 4q23 CBP, EIF4F, AUTS19, EIF4E1, eIF-4E, EIF4EL1 -EIF4E and Breast Cancer
 39
MMP3 11q22.2 SL-1, STMY, STR1, CHDS6, MMP-3, STMY1 -MMP3 and Breast Cancer
 38
XRCC2 7q36.1 FANCU -XRCC2 and Breast Cancer
 38
SIRT1 10q21.3 SIR2, SIR2L1, SIR2alpha -SIRT1 and Breast Cancer
 38
AREG 4q13.3 AR, SDGF, AREGB, CRDGF -AREG and Breast Cancer
 37
ARHGEF1 19q13.2 LSC, GEF1, LBCL2, SUB1.5, P115-RHOGEF -ARHGEF1 and Breast Cancer
 37
CTGF 6q23.2 CCN2, NOV2, HCS24, IGFBP8 -CTGF and Breast Cancer
 37
DROSHA 5p13.3 RN3, ETOHI2, RNASEN, RANSE3L, RNASE3L, HSA242976 -DROSHA and Breast Cancer
 36
TIMP3 22q12.3 SFD, K222, K222TA2, HSMRK222 -TIMP3 and Breast Cancer
 36
MCAM 11q23.3 CD146, MUC18 -MCAM and Breast Cancer
 36
MCL1 1q21.2 TM, EAT, MCL1L, MCL1S, Mcl-1, BCL2L3, MCL1-ES, bcl2-L-3, mcl1/EAT -MCL1 and Breast Cancer
 36
CCL2 17q12 HC11, MCAF, MCP1, MCP-1, SCYA2, GDCF-2, SMC-CF, HSMCR30 -CCL2 and Breast Cancer
 35
BECN1 17q21.31 ATG6, VPS30, beclin1 -BECN1 and Breast Cancer
 35
SNAI2 8q11.21 SLUG, WS2D, SLUGH, SLUGH1, SNAIL2 -SNAI2 and Breast Cancer
 35
MED12 Xq13.1 OKS, FGS1, HOPA, OPA1, OHDOX, ARC240, CAGH45, MED12S, TNRC11, TRAP230 -MED12 and Breast Cancer
 35
AKT3 1q43-q44 MPPH, PKBG, MPPH2, PRKBG, STK-2, PKB-GAMMA, RAC-gamma, RAC-PK-gamma -AKT3 and Breast Cancer
 35
PARL 3q27.1 PSARL, PSARL1, RHBDS1, PRO2207, PSENIP2 -PARL and Breast Cancer
 35
SLC2A1 1p34.2 CSE, PED, DYT9, GLUT, DYT17, DYT18, EIG12, GLUT1, HTLVR, GLUT-1, SDCHCN, GLUT1DS -GLUT1 expression in Breast Cancer
 35
PRLR 5p13.2 HPRL, MFAB, hPRLrI -PRLR and Breast Cancer
 35
FAS 10q23.31 APT1, CD95, FAS1, APO-1, FASTM, ALPS1A, TNFRSF6 -FAS and Breast Cancer
 35
TIMP2 17q25.3 DDC8, CSC-21K Prognostic
 -TIMP2 Expression in Breast Cancer
 34
RUNX2 6p21.1 CCD, AML3, CCD1, CLCD, OSF2, CBFA1, OSF-2, PEA2aA, PEBP2aA, CBF-alpha-1 -RUNX2 and Breast Cancer
 34
ESR2 14q23.2-q23.3 Erb, ESRB, ESTRB, NR3A2, ER-BETA, ESR-BETA -ESR2 and Breast Cancer
 34
PTK6 20q13.33 BRK -PTK6 and Breast Cancer
 34
EGR1 5q31.2 TIS8, AT225, G0S30, NGFI-A, ZNF225, KROX-24, ZIF-268 -EGR1 and Breast Cancer
 34
JUNB 19p13.13 AP-1 -JUNB and Breast Cancer
 33
JAG1 20p12.2 AGS, AHD, AWS, HJ1, AGS1, DCHE, CD339, JAGL1 -JAG1 and Breast Cancer
 33
CHEK1 11q24.2 CHK1 -CHEK1 and Breast Cancer
 33
MTA1 14q32.33 -MTA1 and Breast Cancer
 33
WWOX 16q23.1-q23.2 FOR, WOX1, EIEE28, FRA16D, SCAR12, HHCMA56, PRO0128, SDR41C1, D16S432E -WWOX and Breast Cancer
 33
CTCF 16q22.1 MRD21 -CTCF and Breast Cancer
 32
CDC25A 3p21.31 CDC25A2 -CDC25A and Breast Cancer
 32
BAG1 9p13.3 HAP, BAG-1, RAP46 Overexpression
 -BAG1 overexpression in Breast Cancer
 32
CASP7 10q25.3 MCH3, CMH-1, LICE2, CASP-7, ICE-LAP3 -CASP7 and Breast Cancer
 32
PIN1 19p13.2 DOD, UBL5 -PIN1 and Breast Cancer
 32
FOXO1 13q14.11 FKH1, FKHR, FOXO1A -FOXO1 and Breast Cancer
 32
EPHA2 1p36.13 ECK, CTPA, ARCC2, CTPP1, CTRCT6 -EPHA2 and Breast Cancer
 32
CYP24A1 20q13.2 CP24, HCAI, CYP24, HCINF1, P450-CC24 -CYP24A1 and Breast Cancer
 32
ZNF217 20q13.2 ZABC1 -ZNF217 and Breast Cancer
 32
CD82 11p11.2 R2, 4F9, C33, IA4, ST6, GR15, KAI1, SAR2, TSPAN27 -CD82 and Breast Cancer
 32
EP300 22q13.2 p300, KAT3B, MKHK2, RSTS2 -EP300 and Breast Cancer
 32
KISS1 1q32.1 HH13, KiSS-1 -KISS1 and Breast Cancer
 31
SKP2 5p13.2 p45, FBL1, FLB1, FBXL1 -SKP2 and Breast Cancer
 31
THBS1 15q14 TSP, THBS, TSP1, TSP-1, THBS-1 -THBS1 and Breast Cancer
 31
TCF4 18q21.2 E2-2, ITF2, PTHS, SEF2, FECD3, ITF-2, SEF-2, TCF-4, SEF2-1, SEF2-1A, SEF2-1B, SEF2-1D, bHLHb19 -TCF4 and Breast Cancer
 31
FOXM1 12p13 MPP2, TGT3, HFH11, HNF-3, INS-1, MPP-2, PIG29, FKHL16, FOXM1B, HFH-11, TRIDENT, MPHOSPH2 -FOXM1 and Breast Cancer
 31
RAP1A 1p13.2 RAP1, C21KG, G-22K, KREV1, KREV-1, SMGP21 -Breast Cancer and RAP1A
 31
KLF4 9q31.2 EZF, GKLF -KLF4 and Breast Cancer
 31
IRS1 2q36 HIRS-1 -IRS1 and Breast Cancer
 31
CCNA2 4q27 CCN1, CCNA -CCNA2 and Breast Cancer
 30
MAF 16q23.2 CCA4, AYGRP, c-MAF, CTRCT21 -MAF and Breast Cancer
 30
MTDH 8q22.1 3D3, AEG1, AEG-1, LYRIC, LYRIC/3D3 -MTDH and Breast Cancer
 30
NRG1 8p12 GGF, HGL, HRG, NDF, ARIA, GGF2, HRG1, HRGA, SMDF, MST131, MSTP131, NRG1-IT2 -NRG1 and Breast Cancer
 29
XPC 3p25.1 XP3, RAD4, XPCC, p125 -XPC and Breast Cancer
 29
MYBL2 20q13.12 BMYB, B-MYB -MYBL2 and Breast Cancer
 29
CLOCK 4q12 KAT13D, bHLHe8 -CLOCK and Breast Cancer
 29
LGALS3 14q22.3 L31, GAL3, MAC2, CBP35, GALBP, GALIG, LGALS2 -LGALS3 and Breast Cancer
 29
JUND 19p13.11 AP-1 -JUND and Breast Cancer
 29
GRB2 17q25.1 ASH, Grb3-3, MST084, NCKAP2, MSTP084, EGFRBP-GRB2 -GRB2 and Breast Cancer
 29
TYMS 18p11.32 TS, TMS, HST422 -TYMS and Breast Cancer
 29
STAT5A 17q21.2 MGF, STAT5 -STAT5A and Breast Cancer
 29
SPARC 5q33.1 ON, OI17, BM-40 -SPARC and Breast Cancer
 29
PLK1 16p12.2 PLK, STPK13 -PLK1 and Breast Cancer
 29
PDCD4 10q25.2 H731 -PDCD4 and Breast Cancer
 29
RUNX3 1p36.11 AML2, CBFA3, PEBP2aC -RUNX3 and Breast Cancer
 28
NAT1 8p22 AAC1, MNAT, NATI, NAT-1 -NAT1 and Breast Cancer
 28
CCL5 17q12 SISd, eoCP, SCYA5, RANTES, TCP228, D17S136E, SIS-delta -CCL5 and Breast Cancer
 28
E2F4 16q22.1 E2F-4 -E2F4 and Breast Cancer
 28
COIL 17q22 CLN80, p80-coilin -COIL and Breast Cancer
 28
BCAR1 16q23.1 CAS, CAS1, CASS1, CRKAS, P130Cas -BCAR1 and Breast Cancer
 28
TFF3 21q22.3 ITF, P1B, TFI -TFF3 and Breast Cancer
 28
FGFR4 5q35.2 TKF, JTK2, CD334 -FGFR4 and Breast Cancer
 28
LEPR 1p31.3 OBR, OB-R, CD295, LEP-R, LEPRD -LEPR and Breast Cancer
 28
TERC 3q26.2 TR, hTR, TRC3, DKCA1, PFBMFT2, SCARNA19 -TERC and Breast Cancer
 28
FBXW7 4q31.3 AGO, CDC4, FBW6, FBW7, hAgo, FBX30, FBXW6, SEL10, hCdc4, FBXO30, SEL-10 -FBXW7 and Breast Cancer
 28
NCOA1 2p23 SRC1, KAT13A, RIP160, F-SRC-1, bHLHe42, bHLHe74 -NCOA1 and Breast Cancer
 28
PAK1 11q13.5-q14.1 PAKalpha -PAK1 and Breast Cancer
 28
OSCAR 19q13.42 PIGR3, PIgR-3 -OSCAR and Breast Cancer
 28
SYK 9q22.2 p72-Syk -SYK and Breast Cancer
 27
MMP13 11q22.2 CLG3, MDST, MANDP1, MMP-13 -MMP13 and Breast Cancer
 27
FGF4 11q13.3 HST, KFGF, HST-1, HSTF1, K-FGF, HBGF-4 -FGF4 and Breast Cancer
 27
HEBP1 12p13.1 HBP, HEBP -HEBP1 and Breast Cancer
 27
CYP2C9 10q23.33 CPC9, CYP2C, CYP2C10, CYPIIC9, P450IIC9 -CYP2C9 and Breast Cancer
 27
CBL 11q23.3 CBL2, NSLL, C-CBL, RNF55, FRA11B -Proto-Oncogene Proteins c-cbl and Breast Cancer
 27
TP53BP1 15q15.3 TP53, p202, 53BP1, TDRD30, p53BP1 -TP53BP1 and Breast Cancer
 27
PLAUR 19q13.31 CD87, UPAR, URKR, U-PAR -PLAUR and Breast Cancer
 27
SCGB3A1 5q35.3 HIN1, HIN-1, LU105, UGRP2, PnSP-2 -SCGB3A1 and Breast Cancer
 26
CYP2B6 19q13.2 CPB6, EFVM, IIB1, P450, CYP2B, CYP2B7, CYP2B7P, CYPIIB6 -CYP2B6 and Breast Cancer
 26
MIRLET7B 22q13.31 LET7B, let-7b, MIRNLET7B, hsa-let-7b -MicroRNA let-7b and Breast Cancer
 26
SOX10 22q13.1 DOM, WS4, PCWH, WS2E, WS4C -SOX10 and Breast Cancer
 26
TSG101 11p15.1 TSG10, VPS23 -TSG101 and Breast Cancer
 26
CDK1 10q21.2 CDC2, CDC28A, P34CDC2 -CDK1 and Breast Cancer
 26
LOX 5q23.1 AAT10 -LOX and Breast Cancer
 26
PPM1D 17q23.2 WIP1, PP2C-DELTA -PPM1D and Breast Cancer
 26
HMGA1 6p21.31 HMG-R, HMGIY, HMGA1A -HMGA1 and Breast Cancer
 25
PELP1 17p13.2 MNAR, P160 -PELP1 and Breast Cancer
 25
NOTCH3 19p13.12 IMF2, LMNS, CASIL, CADASIL, CADASIL1 -NOTCH3 and Breast Cancer
 25
CSK 15q24.1 -CSK and Breast Cancer
 25
MRE11 11q21 ATLD, HNGS1, MRE11A, MRE11B -MRE11A and Breast Cancer
 25
WNT5A 3p14.3 hWNT5A -WNT5A and Breast Cancer
 25
MIR126 9q34.3 MIRN126, mir-126, miRNA126 -MicroRNA mir-126 and Breast Cancer
 25
ZEB2 2q22.3 SIP1, SIP-1, ZFHX1B, HSPC082, SMADIP1 -ZEB2 and Breast Cancer
 25
CCN1 1p22.3 GIG1, CYR61, IGFBP10 -CYR61 and Breast Cancer
 25
DDIT3 12q13.3 CHOP, CEBPZ, CHOP10, CHOP-10, GADD153 -DDIT3 and Breast Cancer
 25
XBP1 22q12.1 XBP2, TREB5, XBP-1, TREB-5 -XBP1 and Breast Cancer
 25
DIRAS3 1p31.3 ARHI, NOEY2 -DIRAS3 and Breast Cancer
 24
YBX1 1p34.2 YB1, BP-8, CSDB, DBPB, YB-1, CBF-A, CSDA2, EFI-A, NSEP1, NSEP-1, MDR-NF1 -YBX1 and Breast Cancer
 24
RAD52 12p13.33 -RAD52 and Breast Cancer
 24
HSD17B1 17q21.2 E2DH, HSD17, EDHB17, EDH17B2, SDR28C1, 17-beta-HSD, 20-alpha-HSD -HSD17B1 and Breast Cancer
 24
ELK1 Xp11.23 -ELK1 and Breast Cancer
 24
HMOX1 22q12.3 HO-1, HSP32, HMOX1D, bK286B10 -HMOX1 and Breast Cancer
 24
SNCG 10q23.2 SR, BCSG1 -SNCG and Breast Cancer
 24
YAP1 11q22.1 YAP, YKI, COB1, YAP2, YAP65 -YAP1 and Breast Cancer
 24
CRK 17p13.3 p38, CRKII -CRK and Breast Cancer
 24
VIP 6q25.2 PHM27 -VIP and Breast Cancer
 24
FASLG 1q24.3 APTL, FASL, CD178, CD95L, ALPS1B, CD95-L, TNFSF6, TNLG1A, APT1LG1 -FASLG and Breast Cancer
 23
POLL 10q24.32 BETAN, POLKAPPA -POLL and Breast Cancer
 23
CST6 11q13.1 -CST6 and Breast Cancer
 23
EIF4EBP1 8p11.23 BP-1, 4EBP1, 4E-BP1, PHAS-I -EIF4EBP1 and Breast Cancer
 23
NANOG 12p13.31 -NANOG and Breast Cancer
 23
TP63 3q28 AIS, KET, LMS, NBP, RHS, p40, p51, p63, EEC3, OFC8, p73H, p73L, SHFM4, TP53L, TP73L, p53CP, TP53CP, B(p51A), B(p51B) -TP63 and Breast Cancer
 23
NCOR1 17p12-p11.2 N-CoR, TRAC1, N-CoR1, hN-CoR, PPP1R109 -NCOR1 and Breast Cancer
 23
TACSTD2 1p32.1 EGP1, GP50, M1S1, EGP-1, TROP2, GA7331, GA733-1 -TACSTD2 and Breast Cancer
 23
MMP14 14q11.2 MMP-14, MMP-X1, MT-MMP, MT1MMP, MTMMP1, WNCHRS, MT1-MMP, MT-MMP 1 -MMP14 and Breast Cancer
 23
TRPM2 21q22.3 KNP3, EREG1, TRPC7, LTRPC2, NUDT9H, LTrpC-2, NUDT9L1 -TRPM2 and Breast Cancer
 23
ELAVL1 19p13.2 HUR, Hua, MelG, ELAV1 -ELAVL1 and Breast Cancer
 23
PTHLH 12p11.22 HHM, PLP, BDE2, PTHR, PTHRP -PTHLH and Breast Cancer
 22
MTRR 5p15.31 MSR, cblE -MTRR and Breast Cancer
 22
MIB1 18q11.2 MIB, DIP1, ZZZ6, DIP-1, LVNC7, ZZANK2 -MIB1 and Breast Cancer
 22
NFKBIA 14q13.2 IKBA, MAD-3, NFKBI -NFKBIA and Breast Cancer
 22
BUB1 2q14 BUB1A, BUB1L, hBUB1 -BUB1 and Breast Cancer
 22
OGG1 3p25.3 HMMH, MUTM, OGH1, HOGG1 -OGG1 and Breast Cancer
 22
SCFV 14 -SCFV and Breast Cancer
 22
NOS3 7q36.1 eNOS, ECNOS -NOS3 and Breast Cancer
 22
APOE 19q13.32 AD2, LPG, APO-E, ApoE4, LDLCQ5 -APOE and Breast Cancer
 22
NFE2L2 2q31 NRF2 -NFE2L2 and Breast Cancer
 22
FGF1 5q31.3 AFGF, ECGF, FGFA, ECGFA, ECGFB, FGF-1, HBGF1, HBGF-1, GLIO703, ECGF-beta, FGF-alpha -FGF1 and Breast Cancer
 22
S100A7 1q21.3 PSOR1, S100A7c -S100A7 and Breast Cancer
 22
STAT5B 17q21.2 STAT5 -STAT5B and Breast Cancer
 22
FES 15q26.1 FPS -FES and Breast Cancer
 21
CD9 12p13.31 MIC3, MRP-1, BTCC-1, DRAP-27, TSPAN29, TSPAN-29 -CD9 expression in Breast Cancer
 21
TLR4 9q33.1 TOLL, CD284, TLR-4, ARMD10 -TLR4 and Breast Cancer
 21
RAD51D 17q12 TRAD, R51H3, BROVCA4, RAD51L3 -RAD51D and Breast Cancer
 21
ATF4 22q13.1 CREB2, TXREB, CREB-2, TAXREB67 -ATF4 and Breast Cancer
 21
ARID1A 1p36.11 ELD, B120, CSS2, OSA1, P270, hELD, BM029, MRD14, hOSA1, BAF250, C1orf4, BAF250a, SMARCF1 -ARID1A and Breast Cancer
 21
SERPINE1 7q22.1 PAI, PAI1, PAI-1, PLANH1 -SERPINE1 and Breast Cancer
 21
CDH13 16q23.3 CDHH, P105 -CDH13 and Breast Cancer
 21
TPM3 1q21.3 TM3, TM5, TRK, CFTD, NEM1, TM-5, TM30, CAPM1, TM30nm, TPM3nu, TPMsk3, hscp30, HEL-189, HEL-S-82p, OK/SW-cl.5 -TPM3 and Breast Cancer
 21
FTCDNL1 2q33.1 FONG -FONG and Breast Cancer
 20
NOS2 17q11.2 NOS, INOS, NOS2A, HEP-NOS -NOS2 and Breast Cancer
 20
POLE 12q24.3 FILS, POLE1, CRCS12 -POLE and Breast Cancer
 20
AGR2 7p21.1 AG2, AG-2, HPC8, GOB-4, HAG-2, XAG-2, PDIA17, HEL-S-116 -AGR2 and Breast Cancer
 20
DLC1 8p22 HP, ARHGAP7, STARD12, p122-RhoGAP -Breast Cancer and DLC1
 20
NOTCH4 6p21.32 INT3 -NOTCH4 and Breast Cancer
 20
MSN Xq12 HEL70, IMD50 -MSN and Breast Cancer
 20
TGFB2 1q41 LDS4, G-TSF, TGF-beta2 -TGFB2 and Breast Cancer
 20
TNFSF11 13q14.11 ODF, OPGL, sOdf, CD254, OPTB2, RANKL, TNLG6B, TRANCE, hRANKL2 -TNFSF11 and Breast Cancer
 20
POU5F1 6p21.33 OCT3, OCT4, OTF3, OTF4, OTF-3, Oct-3, Oct-4 -POU5F1 and Breast Cancer
 20
HDAC6 Xp11.23 HD6, JM21, CPBHM, PPP1R90 -HDAC6 and Breast Cancer
 20
CRP 1q23.2 PTX1 -CRP and Breast Cancer
 20
XIST Xq13.2 SXI1, swd66, DXS1089, DXS399E, LINC00001, NCRNA00001 -XIST and Breast Cancer
 20
ARNT 1q21.3 HIF1B, TANGO, bHLHe2, HIF1BETA, HIF-1beta, HIF1-beta, HIF-1-beta -ARNT and Breast Cancer
 20
TIAM1 21q22.11 TIAM-1 -TIAM1 and Breast Cancer
 20
KDR 4q12 FLK1, CD309, VEGFR, VEGFR2 -KDR and Breast Cancer
 20
SPP1 4q22.1 OPN, BNSP, BSPI, ETA-1 -SPP1 and Breast Cancer
 19
MAP2K1 15q22.31 CFC3, MEK1, MKK1, MAPKK1, PRKMK1 -MAP2K1 and Breast Cancer
 19
GSTA1 6p12.2 GST2, GTH1, GSTA1-1, GST-epsilon -GSTA1 and Breast Cancer
 19
MMP11 22q11.23 ST3, SL-3, STMY3 Prognostic
 -MMP11 Expression in Breast Cancer
 19
WNT3A 1q42.13 -WNT3A and Breast Cancer
 19
KDM1A 1p36.12 AOF2, CPRF, KDM1, LSD1, BHC110 -KDM1A and Breast Cancer
 19
SMAD7 18q21.1 CRCS3, MADH7, MADH8 -SMAD7 and Breast Cancer
 19
CCND3 6p21.1 -CCND3 and Breast Cancer
 19
XRCC4 5q14.2 SSMED -XRCC4 and Breast Cancer
 19
GPX1 3p21.31 GPXD, GSHPX1 -GPX1 and Breast Cancer
 19
ETS2 21q22.2 ETS2IT1 -ETS2 and Breast Cancer
 19
BBC3 19q13.32 JFY1, PUMA, JFY-1 -BBC3 and Breast Cancer
 19
TCF7L2 10q25.2-q25.3 TCF4, TCF-4 -TCF7L2 and Breast Cancer
 19
XRCC6 22q13.2 ML8, KU70, TLAA, CTC75, CTCBF, G22P1 -XRCC6 and Breast Cancer
 19
CREB1 2q34 CREB -CREB1 and Breast Cancer
 19
CLU 8p21.1 CLI, AAG4, APOJ, CLU1, CLU2, KUB1, SGP2, APO-J, SGP-2, SP-40, TRPM2, TRPM-2, NA1/NA2 -CLU and Breast Cancer
 19
MECP2 Xq28 RS, RTS, RTT, PPMX, MRX16, MRX79, MRXSL, AUTSX3, MRXS13 -MECP2 and Breast Cancer
 19
MUTYH 1p34.1 MYH -MUTYH and Breast Cancer
 19
CDC25C 5q31.2 CDC25, PPP1R60 -CDC25C and Breast Cancer
 19
ITGB3 17q21.32 GT, CD61, GP3A, BDPLT2, GPIIIa, BDPLT16 -ITGB3 and Breast Cancer
 19
M6PR 12p13 SMPR, MPR46, CD-MPR, MPR 46, MPR-46 -M6PR and Breast Cancer
 19
PRKCA 17q24.2 AAG6, PKCA, PRKACA, PKC-alpha -PRKCA and Breast Cancer
 19
HIC1 17p13.3 hic-1, ZBTB29, ZNF901 -HIC1 and Breast Cancer
 19
BIK 22q13.2 BP4, NBK, BIP1 -BIK and Breast Cancer
 18
ERCC4 16p13.12 XPF, RAD1, FANCQ, XFEPS, ERCC11 -ERCC4 and Breast Cancer
 18
RELB 19q13.32 IREL, I-REL, REL-B -RELB and Breast Cancer
 18
CTTN 11q13.3 EMS1 -CTTN and Breast Cancer
 18
HDAC3 5q31.3 HD3, RPD3, RPD3-2 -HDAC3 and Breast Cancer
 18
DAPK1 9q21.33 DAPK -DAPK1 and Breast Cancer
 18
BNIP3 10q26.3 NIP3 -BNIP3 and Breast Cancer
 18
PITX2 4q25 RS, RGS, ARP1, Brx1, IDG2, IGDS, IHG2, PTX2, RIEG, ASGD4, IGDS2, IRID2, Otlx2, RIEG1 -PITX2 and Breast Cancer
 18
ID2 2p25 GIG8, ID2A, ID2H, bHLHb26 -ID2 Expression in Breast Cancer
 18
CYP2C8 10q23.33 CPC8, CYPIIC8, MP-12/MP-20 -CYP2C8 and Breast Cancer
 18
CXCL2 4q13.3 GRO2, GROb, MIP2, MIP2A, SCYB2, MGSA-b, MIP-2a, CINC-2a -CXCL2 and Breast Cancer
 18
NEK2 1q32.3 NLK1, RP67, NEK2A, HsPK21, PPP1R111 -NEK2 and Breast Cancer
 18
CYP27B1 12q14.1 VDR, CP2B, CYP1, PDDR, VDD1, VDDR, VDDRI, CYP27B, P450c1, CYP1alpha -CYP27B1 and Breast Cancer
 18
SHC1 1q21.3 SHC, SHCA -SHC1 and Breast Cancer
 18
ADAM12 10q26.2 MCMP, MLTN, CAR10, MLTNA, MCMPMltna, ADAM12-OT1 -ADAM12 and Breast Cancer
 18
HLA-G 6p22.1 MHC-G -HLA-G and Breast Cancer
 17
RAD51B 14q24.1 REC2, R51H2, RAD51L1 -RAD51B and Breast Cancer
 17
SIX1 14q23.1 BOS3, TIP39, DFNA23 -SIX1 and Breast Cancer
 17
CCR7 17q21.2 BLR2, EBI1, CCR-7, CD197, CDw197, CMKBR7, CC-CKR-7 -CCR7 and Breast Cancer
 17
ACTB 7p22.1 BRWS1, PS1TP5BP1 -ACTB and Breast Cancer
 17
NFKB1 4q24 p50, KBF1, p105, EBP-1, CVID12, NF-kB1, NFKB-p50, NFkappaB, NF-kappaB, NFKB-p105, NF-kappa-B -NFKB1 and Breast Cancer
 17
UBE2C 20q13.12 UBCH10, dJ447F3.2 -UBE2C and Breast Cancer
 17
PMAIP1 18q21.32 APR, NOXA -PMAIP1 and Breast Cancer
 17
FYN 6q21 SLK, SYN, p59-FYN -FYN and Breast Cancer
 17
DNMT3A 2p23 TBRS, DNMT3A2, M.HsaIIIA -DNMT3A and Breast Cancer
 17
RARB 3p24.2 HAP, RRB2, NR1B2, MCOPS12, RARbeta1 -RARB and Breast Cancer
 17
CTLA4 2q33 CD, GSE, GRD4, ALPS5, CD152, CTLA-4, IDDM12, CELIAC3 -CTLA4 and Breast Cancer
 17
HFE 6p22.2 HH, HFE1, HLA-H, MVCD7, TFQTL2 -HFE and Breast Cancer
 17
FASN 17q25.3 FAS, OA-519, SDR27X1 -FASN and Breast Cancer
 17
IRS2 13q34 IRS-2 -IRS2 and Breast Cancer
 17
CD68 17p13.1 GP110, LAMP4, SCARD1 -CD68 and Breast Cancer
 17
PTTG1 5q33.3 EAP1, PTTG, HPTTG, TUTR1 -PTTG1 and Breast Cancer
 16
MBD2 18q21.2 DMTase, NY-CO-41 -MBD2 and Breast Cancer
 16
FEN1 11q12.2 MF1, RAD2, FEN-1 -FEN1 and Breast Cancer
 16
E2F2 1p36.12 E2F-2 -E2F2 and Breast Cancer
 16
SPDEF 6p21.3 PDEF, bA375E1.3 -SPDEF and Breast Cancer
 16
SATB1 3p23 -SATB1 and Breast Cancer
 16
CTNNA1 5q31.2 MDPT2, CAP102 -CTNNA1 and Breast Cancer
 16
IL11 19q13.42 AGIF, IL-11 -IL11 and Breast Cancer
 16
CDC20 1p34.2 CDC20A, p55CDC, bA276H19.3 -CDC20 and Breast Cancer
 16
SOD1 21q22.11 ALS, SOD, ALS1, IPOA, hSod1, HEL-S-44, homodimer -SOD1 and Breast Cancer
 16
KDM5B 1q32.1 CT31, PLU1, PUT1, MRT65, PLU-1, JARID1B, PPP1R98, RBP2-H1, RBBP2H1A -KDM5B and Breast Cancer
 16
E2F3 6p22.3 E2F-3 -E2F3 and Breast Cancer
 16
CREBBP 16p13.3 CBP, RSTS, KAT3A, RSTS1 -CREBBP and Breast Cancer
 16
GREB1 2p25.1 -GREB1 and Breast Cancer
 16
BMP4 14q22.2 ZYME, BMP2B, OFC11, BMP2B1, MCOPS6 -BMP4 and Breast Cancer
 16
STMN1 1p36.11 Lag, SMN, OP18, PP17, PP19, PR22, LAP18, C1orf215 -STMN1 and Breast Cancer
 16
FOXC2 16q24.1 LD, MFH1, MFH-1, FKHL14 -FOXC2 and Breast Cancer
 16
HSPB1 7q11.23 CMT2F, HMN2B, HSP27, HSP28, Hsp25, SRP27, HS.76067, HEL-S-102 -HSPB1 and Breast Cancer
 16
FCGR3A 1q23.3 CD16, FCG3, CD16A, FCGR3, IGFR3, IMD20, FCR-10, FCRIII, FCGRIII, FCRIIIA -FCGR3A and Breast Cancer
 16
RAD21 8q24.11 HR21, MCD1, NXP1, SCC1, CDLS4, hHR21, HRAD21 -RAD21 and Breast Cancer
 15
BMP2 20p12.3 BDA2, BMP2A, SSFSC -BMP2 and Breast Cancer
 15
MARCO 2q14.2 SCARA2 -MARCO and Breast Cancer
 15
DLX4 17q21.33 BP1, DLX7, DLX8, DLX9, OFC15 -DLX4 and Breast Cancer
 15
CKAP4 12q23.3 p63, CLIMP-63, ERGIC-63 -CKAP4 and Breast Cancer
 15
PRKDC 8q11.21 HYRC, p350, DNAPK, DNPK1, HYRC1, IMD26, XRCC7, DNA-PKcs -PRKDC and Breast Cancer
 15
TBX3 12q24.21 UMS, XHL, TBX3-ISO -TBX3 and Breast Cancer
 15
KEAP1 19p13.2 INrf2, KLHL19 -KEAP1 and Breast Cancer
 15
SIPA1 11q13.1 SPA1 -SIPA1 and Breast Cancer
 15
MAP2K4 17p12 JNKK, MEK4, MKK4, SEK1, SKK1, JNKK1, SERK1, MAPKK4, PRKMK4, SAPKK1, SAPKK-1 -MAP2K4 and Breast Cancer
 15
BTG2 1q32.1 PC3, APRO1, TIS21 -BTG2 and Breast Cancer
 15
TUBB3 16q24.3 CDCBM, FEOM3, TUBB4, CDCBM1, CFEOM3, beta-4, CFEOM3A -TUBB3 and Breast Cancer
 15
WEE1 11p15.4 WEE1A, WEE1hu -WEE1 and Breast Cancer
 15
KRT19 17q21.2 K19, CK19, K1CS -KRT19 and Breast Cancer
 15
KL 13q13.1 -KL and Breast Cancer
 15
RRM1 11p15.4 R1, RR1, RIR1 -RRM1 and Breast Cancer
 15
GADD45A 1p31.3 DDIT1, GADD45 -GADD45A and Breast Cancer
 15
BMP6 6p24.3 VGR, VGR1 -BMP6 and Breast Cancer
 15
CAST 5q15 BS-17, PLACK -CAST and Breast Cancer
 15
IGFBP1 7p12.3 AFBP, IBP1, PP12, IGF-BP25, hIGFBP-1 -IGFBP1 and Breast Cancer
 15
CLDN1 3q28-q29 CLD1, SEMP1, ILVASC -CLDN1 and Breast Cancer
 15
HMGB1 13q12.3 HMG1, HMG3, HMG-1, SBP-1 -HMGB1 and Breast Cancer
 15
PIK3CB 3q22.3 PI3K, PIK3C1, P110BETA, PI3KBETA -PIK3CB and Breast Cancer
 15
WNT3 17q21.31-q21.32 INT4, TETAMS -WNT3 and Breast Cancer
 15
PWAR1 15q11.2 PAR1, PAR-1, D15S227E -PAR1 and Breast Cancer
 15
RRM2 2p25-p24 R2, RR2, RR2M -RRM2 and Breast Cancer
 15
PRKN 6q26 PDJ, AR-JP, LPRS2, PARK2 -PARK2 and Breast Cancer
 15
ELF3 1q32.1 ERT, ESX, EPR-1, ESE-1 -ELF3 and Breast Cancer
 15
SSTR2 17q25.1 -SSTR2 and Breast Cancer
 15
APOD 3q29 -APOD and Breast Cancer
 15
TP73 1p36.32 P73 -TP73 and Breast Cancer
 15
ZNF350 19q13.41 ZFQR, ZBRK1 -ZNF350 and Breast Cancer
 15
ATF3 1q32.3 -ATF3 and Breast Cancer
 15
FOXC1 6p25 ARA, IGDA, IHG1, FKHL7, IRID1, RIEG3, FREAC3, FREAC-3 -FOXC1 and Breast Cancer
 15
TXNIP 1q21.1 THIF, VDUP1, ARRDC6, HHCPA78, EST01027 -TXNIP and Breast Cancer
 15
MAD2L1 4q27 MAD2, HSMAD2 -MAD2L1 and Breast Cancer
 14
BAP1 3p21.1 UCHL2, hucep-6, HUCEP-13 -BAP1 and Breast Cancer
 14
S100A8 1q21.3 P8, MIF, NIF, CAGA, CFAG, CGLA, L1Ag, MRP8, CP-10, MA387, 60B8AG -S100A8 and Breast Cancer
 14
MAPK8 10q11.22 JNK, JNK1, PRKM8, SAPK1, JNK-46, JNK1A2, SAPK1c, JNK21B1/2 -MAPK8 and Breast Cancer
 14
RAF1 3p25.2 NS5, CRAF, Raf-1, c-Raf, CMD1NN -RAF1 and Breast Cancer
 14
NCOR2 12q24 SMRT, TRAC, CTG26, SMRTE, TRAC1, N-CoR2, TNRC14, TRAC-1, SMAP270, SMRTE-tau -NCOR2 and Breast Cancer
 14
MIF 22q11.23 GIF, GLIF, MMIF -MIF and Breast Cancer
 14
ATG5 6q21 ASP, APG5, APG5L, hAPG5, APG5-LIKE -ATG5 and Breast Cancer
 14
ANXA1 9q21.13 ANX1, LPC1 -ANXA1 and Breast Cancer
 14
SRD5A2 2p23 -SRD5A2 and Breast Cancer
 14
CCNE2 8q22.1 CYCE2 -CCNE2 and Breast Cancer
 14
LCN2 9q34.11 p25, 24p3, MSFI, NGAL -LCN2 and Breast Cancer
 14
IGFBP5 2q35 IBP5 -IGFBP5 and Breast Cancer
 14
CARM1 19p13.2 PRMT4 -CARM1 and Breast Cancer
 14
TRAF2 9q34.3 TRAP, TRAP3, MGC:45012 -TRAF2 and Breast Cancer
 14
HAS2 8q24.13 -HAS2 and Breast Cancer
 14
MALAT1 11q13.1 HCN, NEAT2, PRO2853, LINC00047, NCRNA00047 -MALAT1 and Breast Cancer
 14
BRD4 19p13.12 CAP, MCAP, HUNK1, HUNKI -BRD4 and Breast Cancer
 14
PEBP1 12q24.23 PBP, HCNP, PEBP, RKIP, HCNPpp, PEBP-1, HEL-210, HEL-S-34 -PEBP1 and Breast Cancer
 14
TRPS1 8q23.3 GC79, LGCR -TRPS1 and Breast Cancer
 14
KLK10 19q13.41 NES1, PRSSL1 -KLK10 and Breast Cancer
 14
PDK1 2q31.1 -PDK1 and Breast Cancer
 14
MED1 17q12 PBP, CRSP1, RB18A, TRIP2, PPARBP, CRSP200, DRIP205, DRIP230, PPARGBP, TRAP220 -MED1 and Breast Cancer
 14
VIM 10p13 HEL113, CTRCT30 -VIM and Breast Cancer
 14
TNFRSF10A 8p21.3 DR4, APO2, CD261, TRAILR1, TRAILR-1 -TNFRSF10A and Breast Cancer
 14
CD80 3q13.33 B7, BB1, B7-1, B7.1, LAB7, CD28LG, CD28LG1 -CD80 and Breast Cancer
 14
RFC1 4p14 A1, RFC, PO-GA, RECC1, MHCBFB, RFC140 -RFC1 and Breast Cancer
 14
REL 2p13-p12 C-Rel -REL and Breast Cancer
 14
HOXB7 17q21.32 HOX2, HOX2C, HHO.C1, Hox-2.3 -HOXB7 and Breast Cancer
 14
GHRH 20q11.23 GRF, INN, GHRF -GHRH and Breast Cancer
 14
AKR1C3 10p15.1 DD3, DDX, PGFS, HAKRB, HAKRe, HA1753, HSD17B5, hluPGFS -AKR1C3 and Breast Cancer
 13
GDF15 19p13.11 PDF, MIC1, PLAB, MIC-1, NAG-1, PTGFB, GDF-15 -GDF15 and Breast Cancer
 13
CSF1 1p13.3 MCSF, CSF-1 -CSF1 and Breast Cancer
 13
EIF3E 8q23.1 INT6, EIF3S6, EIF3-P48, eIF3-p46 -EIF3E and Breast Cancer
 13
HDAC2 6q21 HD2, RPD3, YAF1 -HDAC2 and Breast Cancer
 13
PIK3R1 5q13.1 p85, AGM7, GRB1, IMD36, p85-ALPHA -PIK3R1 and Breast Cancer
 13
RHOB 2p24 ARH6, ARHB, RHOH6, MST081, MSTP081 -RHOB and Breast Cancer
 13
SERPINB5 18q21.33 PI5, maspin -SERPINB5 and Breast Cancer
 13
TNFRSF10B 8p21.3 DR5, CD262, KILLER, TRICK2, TRICKB, ZTNFR9, TRAILR2, TRICK2A, TRICK2B, TRAIL-R2, KILLER/DR5 -TNFRSF10B and Breast Cancer
 13
MOS 8q12.1 MSV -MOS and Breast Cancer
 13
LMO4 1p22.3 -LMO4 and Breast Cancer
 13
IRF1 5q31.1 MAR, IRF-1 -IRF1 and Breast Cancer
 13
HOXA5 7p15.2 HOX1, HOX1C, HOX1.3 -HOXA5 and Breast Cancer
 13
ADIPOR1 1q32.1 CGI45, PAQR1, ACDCR1, CGI-45, TESBP1A -ADIPOR1 and Breast Cancer
 13
LEF1 4q25 LEF-1, TCF10, TCF7L3, TCF1ALPHA -LEF1 and Breast Cancer
 13
KLF5 13q22.1 CKLF, IKLF, BTEB2 -KLF5 and Breast Cancer
 13
AXL 19q13.2 ARK, UFO, JTK11, Tyro7 -AXL and Breast Cancer
 13
CLDN4 7q11.23 CPER, CPE-R, CPETR, CPETR1, WBSCR8, hCPE-R -CLDN4 and Breast Cancer
 13
CIC 19q13.2 -CIC and Breast Cancer
 13
SOCS3 17q25.3 CIS3, SSI3, ATOD4, Cish3, SSI-3, SOCS-3 -SOCS3 and Breast Cancer
 13
HOXD10 2q31.1 HOX4, HOX4D, HOX4E, Hox-4.4 -HOXD10 and Breast Cancer
 13
SOX4 6p22.3 EVI16 -SOX4 and Breast Cancer
 13
PIGS 17q11.2 -PIGS and Breast Cancer
 13
POSTN 13q13.3 PN, OSF2, OSF-2, PDLPOSTN -POSTN and Breast Cancer
 13
ADAM9 8p11.22 MCMP, MDC9, CORD9, Mltng -ADAM9 and Breast Cancer
 12
WWTR1 3q25.1 TAZ -WWTR1 and Breast Cancer
 12
CXCL10 4q21.1 C7, IFI10, INP10, IP-10, crg-2, mob-1, SCYB10, gIP-10 -CXCL10 and Breast Cancer
 12
WISP3 6q21 PPD, CCN6, LIBC, PPAC, WISP-3 -WISP3 and Breast Cancer
 12
IL18 11q23.1 IGIF, IL-18, IL-1g, IL1F4 -IL18 and Breast Cancer
 12
WRN 8p12 RECQ3, RECQL2, RECQL3 -WRN and Breast Cancer
 12
ABCC2 10q24.2 DJS, MRP2, cMRP, ABC30, CMOAT -ABCC2 and Breast Cancer
 12
RAB25 1q22 CATX-8, RAB11C -RAB25 and Breast Cancer
 12
UGT2B7 4q13.2 UGT2B9, UDPGTH2, UDPGT2B7, UDPGTh-2, UDPGT 2B7, UDPGT 2B9 -UGT2B7 and Breast Cancer
 12
PRINS 10p12.1 NCRNA00074 -PRINS and Breast Cancer
 12
NDRG1 8q24.22 GC4, RTP, DRG1, NDR1, NMSL, TDD5, CAP43, CMT4D, DRG-1, HMSNL, RIT42, TARG1, PROXY1 -NDRG1 and Breast Cancer
 12
RPS6KB1 17q23.1 S6K, PS6K, S6K1, STK14A, p70-S6K, p70 S6KA, p70-alpha, S6K-beta-1, p70(S6K)-alpha -RPS6KB1 and Breast Cancer
 12
NFKB2 10q24.32 p52, p100, H2TF1, LYT10, CVID10, LYT-10, NF-kB2, p49/p100 -NFKB2 and Breast Cancer
 12
BLM 15q26.1 BS, RECQ2, RECQL2, RECQL3 -BLM and Breast Cancer
 12
CCR5 3p21.31 CKR5, CCR-5, CD195, CKR-5, CCCKR5, CMKBR5, IDDM22, CC-CKR-5 -CCR5 and Breast Cancer
 12
TGFB3 14q24.3 ARVD, LDS5, RNHF, ARVD1, TGF-beta3 -TGFB3 and Breast Cancer
 12
LIF 22q12.2 CDF, DIA, HILDA, MLPLI -LIF and Breast Cancer
 12
ADH1C 4q23 ADH3 -ADH1C and Breast Cancer
 12
IL17C 16q24.2 CX2, IL-17C -IL17C and Breast Cancer
 12
BCAR3 1p22.1 NSP2, AND-34, SH2D3B -BCAR3 and Breast Cancer
 12
SKI 1p36.33-p36.32 SGS, SKV -SKI and Breast Cancer
 12
RBBP8 18q11.2 RIM, COM1, CTIP, JWDS, SAE2, SCKL2 -RBBP8 and Breast Cancer
 12
NFIB 9p23-p22.3 CTF, NF1-B, NFI-B, NFIB2, NFIB3, NF-I/B, NFI-RED, HMGIC/NFIB -NFIB and Breast Cancer
 12
LYN 8q12.1 JTK8, p53Lyn, p56Lyn -LYN and Breast Cancer
 12
LATS1 6q25.1 wts, WARTS -LATS1 and Breast Cancer
 12
COL1A1 17q21.33 OI1, OI2, OI3, OI4, EDSC -COL1A1 and Breast Cancer
 12
AMPH 7p14.1 AMPH1 Overexpression
 -AMPH Expression in Stiff-Person Syndrome associated Breast Cancer
12
TPX2 20q11.21 DIL2, p100, DIL-2, HCTP4, FLS353, HCA519, REPP86, C20orf1, C20orf2, GD:C20orf1 -TPX2 and Breast Cancer
 12
TOPBP1 3q22.1 TOP2BP1 -TOPBP1 and Breast Cancer
 12
CDC25B 20p13 -CDC25B and Breast Cancer
 12
SLC9A1 1p36.11 APNH, NHE1, LIKNS, NHE-1, PPP1R143 -SLC9A1 and Breast Cancer
 12
YY1AP1 1q22 GRNG, HCCA1, HCCA2, YY1AP -YY1AP1 and Breast Cancer
 12
ANGPT2 8p23.1 ANG2, AGPT2 -ANGPT2 and Breast Cancer
 12
HSF1 8q24.3 HSTF1 -HSF1 and Breast Cancer
 12
SUV39H1 Xp11.23 MG44, KMT1A, SUV39H, H3-K9-HMTase 1 -SUV39H1 and Breast Cancer
 12
DUSP1 5q35.1 HVH1, MKP1, CL100, MKP-1, PTPN10 -DUSP1 and Breast Cancer
 11
TBX2 17q23.2 -TBX2 and Breast Cancer
 11
MDC1 6p21.33 NFBD1 -MDC1 and Breast Cancer
 11
PSEN2 1q42.13 AD4, PS2, AD3L, STM2, CMD1V -PSEN2 and Breast Cancer
 11
TNFRSF11B 8q24.12 OPG, TR1, OCIF, PDB5 -TNFRSF11B and Breast Cancer
 11
TLR3 4q35.1 CD283, IIAE2 -TLR3 and Breast Cancer
 11
PYCARD 16p11.2 ASC, TMS, TMS1, CARD5, TMS-1 -PYCARD and Breast Cancer
 11
DPYD 1p21.3 DHP, DPD, DHPDHASE -DPYD and Breast Cancer
 11
PLAU 10q22.2 ATF, QPD, UPA, URK, u-PA, BDPLT5 -PLAU and Breast Cancer
 11
CDH2 18q12.1 CDHN, NCAD, CD325, CDw325 -CDH2 and Breast Cancer
 11
NR5A2 1q32.1 B1F, CPF, FTF, B1F2, LRH1, LRH-1, FTZ-F1, hB1F-2, FTZ-F1beta -NR5A2 and Breast Cancer
 11
TRA 14q11.2 IMD7, TCRA, TCRD, TRA@, TRAC -TRA and Breast Cancer
 11
DHFR 5q14.1 DYR, DHFRP1 -DHFR and Breast Cancer
 11
MIR127 14q32.2 MIRN127, mir-127, miRNA127 -MicroRNA miR-127 and Breast Cancer
 11
NGFR 17q21.33 CD271, p75NTR, TNFRSF16, p75(NTR), Gp80-LNGFR -NGFR and Breast Cancer
 11
MIR107 10q23.31 MIRN107, miR-107 -MicroRNA mir-107 and Breast Cancer
 11
MARS 12q13.3 MRS, ILLD, CMT2U, ILFS2, METRS, MTRNS, SPG70 -MARS and Breast Cancer
 11
HOXA1 7p15.2 BSAS, HOX1, HOX1F -HOXA1 and Breast Cancer
 11
RARS 5q34 HLD9, ArgRS, DALRD1 -RARS and Breast Cancer
 11
INSR 19p13.2 HHF5, CD220 -INSR and Breast Cancer
 11
CD46 1q32.2 MCP, TLX, AHUS2, MIC10, TRA2.10 -CD46 and Breast Cancer
 11
RECK 9p13.3 ST15 -RECK and Breast Cancer
 11
IL6R 1q21.3 IL6Q, gp80, CD126, IL6RA, IL6RQ, IL-6RA, IL-6R-1 -IL6R and Breast Cancer
 11
TPD52 8q21.13 D52, N8L, PC-1, PrLZ, hD52 -TPD52 and Breast Cancer
 11
ZFP36 19q13.2 TTP, G0S24, GOS24, TIS11, NUP475, zfp-36, RNF162A -ZFP36 and Breast Cancer
 11
ALCAM 3q13.1 MEMD, CD166 -ALCAM and Breast Cancer
 11
TES 7q31.2 TESS, TESS-2 -TES and Breast Cancer
 11
GPC3 Xq26.2 SGB, DGSX, MXR7, SDYS, SGBS, OCI-5, SGBS1, GTR2-2 -GPC3 and Breast Cancer
 11
SFRP2 4q31.3 FRP-2, SARP1, SDF-5 -SFRP2 and Breast Cancer
 11
BIRC3 11q22.2 AIP1, API2, MIHC, CIAP2, HAIP1, HIAP1, MALT2, RNF49, c-IAP2 -BIRC3 and Breast Cancer
 10
NAV1 1q32.1 POMFIL3, UNC53H1, STEERIN1 -NAV1 and Breast Cancer
 10
IL6ST 5q11.2 CD130, GP130, CDW130, IL-6RB -IL6ST and Breast Cancer
 10
CCNB2 15q22.2 HsT17299 -CCNB2 and Breast Cancer
 10
SDC1 2p24.1 SDC, CD138, SYND1, syndecan -SDC1 and Breast Cancer
 10
NEDD4 15q21.3 RPF1, NEDD4-1 -NEDD4 and Breast Cancer
 10
WIF1 12q14.3 WIF-1 -WIF1 and Breast Cancer
 10
SOX17 8q11.23 VUR3 -SOX17 and Breast Cancer
 10
DACH1 13q21.33 DACH -DACH1 and Breast Cancer
 10
ERCC5 13q33.1 XPG, UVDR, XPGC, COFS3, ERCM2, ERCC5-201 -ERCC5 and Breast Cancer
 10
MTA2 11q12.3 PID, MTA1L1 -MTA2 and Breast Cancer
 10
PGK1 Xq21.1 PGKA, MIG10, HEL-S-68p -PGK1 and Breast Cancer
 10
FURIN 15q26.1 FUR, PACE, SPC1, PCSK3 -FURIN and Breast Cancer
 10
S100A9 1q21.3 MIF, NIF, P14, CAGB, CFAG, CGLB, L1AG, LIAG, MRP14, 60B8AG, MAC387 -S100A9 and Breast Cancer
 10
TLR9 3p21.2 CD289 -TLR9 and Breast Cancer
 10
LGALS1 22q13.1 GBP, GAL1 -LGALS1 and Breast Cancer
 10
ISG15 1p36.33 G1P2, IP17, UCRP, IFI15, IMD38, hUCRP -ISG15 and Breast Cancer
 10
EPHB6 7q34 HEP -EPHB6 and Breast Cancer
 10
ST3 11q13-q23 CCTS, TSHL -ST3 and Breast Cancer
 10
HNRNPA2B1 7p15.2 RNPA2, HNRPA2, HNRPB1, SNRPB1, HNRNPA2, HNRNPB1, IBMPFD2, HNRPA2B1 -HNRNPA2B1 and Breast Cancer
 10
CXCL13 4q21.1 BLC, BCA1, ANGIE, BCA-1, BLR1L, ANGIE2, SCYB13 -CXCL13 and Breast Cancer
 10
MRTFA 22q13.1-q13.2 MAL, MKL, BSAC, MKL1, MRTF-A -MKL1 and Breast Cancer
 10
L1CAM Xq28 S10, HSAS, MASA, MIC5, SPG1, CAML1, CD171, HSAS1, N-CAML1, NCAM-L1, N-CAM-L1 -L1CAM and Breast Cancer
 10
TGFBR3 1p22.1 BGCAN, betaglycan -TGFBR3 and Breast Cancer
 10
DDB2 11p11.2 XPE, DDBB, UV-DDB2 -DDB2 and Breast Cancer
 10
CTSD 11p15.5 CPSD, CLN10, HEL-S-130P -CTSD and Breast Cancer
 10
HOTAIR 12q13.13 HOXAS, HOXC-AS4, HOXC11-AS1, NCRNA00072 -HOTAIR and Breast Cancer
 10
IL4 5q31.1 BSF1, IL-4, BCGF1, BSF-1, BCGF-1 -IL4 and Breast Cancer
 10
YWHAZ 8q22.3 HEL4, YWHAD, KCIP-1, HEL-S-3, HEL-S-93, 14-3-3-zeta -YWHAZ and Breast Cancer
 10
PPARG 3p25.2 GLM1, CIMT1, NR1C3, PPARG1, PPARG2, PPARgamma -PPARG and Breast Cancer
 10
RPA1 17p13.3 HSSB, RF-A, RP-A, REPA1, RPA70, MST075 -RPA1 and Breast Cancer
 10
ABCC5 3q27.1 MRP5, SMRP, ABC33, MOATC, MOAT-C, pABC11, EST277145 -ABCC5 and Breast Cancer
 10
CD74 5q33.1 II, DHLAG, HLADG, Ia-GAMMA -CD74 and Breast Cancer
 10
IKBKE 1q32.1 IKKE, IKKI, IKK-E, IKK-i -IKBKE and Breast Cancer
 10
CUL4A 13q34 -CUL4A and Breast Cancer
 10
IBSP 4q22.1 BSP, BNSP, SP-II, BSP-II -IBSP and Breast Cancer
 10
YES1 18p11.32 Yes, c-yes, HsT441, P61-YES -Proto-Oncogene Proteins c-yes and Breast Cancer
 10
BMP7 20q13.31 OP-1 -BMP7 and Breast Cancer
 10
PTPN1 20q13.13 PTP1B -PTPN1 and Breast Cancer
 10
IL2RG Xq13.1 P64, CIDX, IMD4, CD132, SCIDX, IL-2RG, SCIDX1 -IL2RG and Breast Cancer
 10
TCF3 19p13.3 E2A, E47, AGM8, ITF1, VDIR, TCF-3, bHLHb21 -TCF3 and Breast Cancer
 10
ANXA2 15q22.2 P36, ANX2, LIP2, LPC2, CAL1H, LPC2D, ANX2L4, PAP-IV, HEL-S-270 -ANXA2 and Breast Cancer
 10
DDX5 17q23.3 p68, HLR1, G17P1, HUMP68 -DDX5 and Breast Cancer
 10
EPHB4 7q22.1 HTK, MYK1, HFASD, TYRO11 -EPHB4 and Breast Cancer
 10
RHOBTB2 8p21.3 DBC2 -RHOBTB2 and Breast Cancer
 10
STAT6 12q13.3 STAT6B, STAT6C, D12S1644, IL-4-STAT -STAT6 and Breast Cancer
 10
SQSTM1 5q35.3 p60, p62, A170, DMRV, OSIL, PDB3, ZIP3, p62B, NADGP, FTDALS3 -SQSTM1 and Breast Cancer
 10
CEBPD 8q11.21 CELF, CRP3, C/EBP-delta, NF-IL6-beta -CEBPD and Breast Cancer
 10
NME2 17q21.33 PUF, NDKB, NDPKB, NM23B, NDPK-B, NM23-H2 -NME2 and Breast Cancer
 10
ADRB2 5q32 BAR, B2AR, ADRBR, ADRB2R, BETA2AR -ADRB2 and Breast Cancer
 9
REST 4q12 WT6, XBR, NRSF -REST and Breast Cancer
 9
ABCC3 17q21.33 MLP2, MRP3, ABC31, MOAT-D, cMOAT2, EST90757 -ABCC3 and Breast Cancer
 9
CDC6 17q21.2 CDC18L, HsCDC6, MGORS5, HsCDC18 -CDC6 and Breast Cancer
 9
SREBF1 17p11.2 SREBP1, bHLHd1, SREBP1a, SREBP-1c -SREBF1 and Breast Cancer
 9
CDH3 16q22.1 CDHP, HJMD, PCAD -CDH3 and Breast Cancer
 9
B2M 15q21.1 IMD43 -B2M and Breast Cancer
 9
AXIN1 16p13.3 AXIN, PPP1R49 -AXIN1 and Breast Cancer
 9
KPNA2 17q24.2 QIP2, RCH1, IPOA1, SRP1alpha, SRP1-alpha -KPNA2 and Breast Cancer
 9
PER2 2q37.3 FASPS, FASPS1 -PER2 and Breast Cancer
 9
DKK3 11p15.3 RIG, REIC -DKK3 and Breast Cancer
 9
SIRT3 11p15.5 SIR2L3 -SIRT3 and Breast Cancer
 9
IFNG 12q15 IFG, IFI -IFNG and Breast Cancer
 9
COPS5 8q13.1 CSN5, JAB1, SGN5, MOV-34 -COPS5 and Breast Cancer
 9
UHRF1 19p13.3 Np95, hNP95, ICBP90, RNF106, TDRD22, hUHRF1, huNp95 -UHRF1 and Breast Cancer
 9
PTPN13 4q21.3 PNP1, FAP-1, PTP1E, PTPL1, PTPLE, PTP-BL, hPTP1E, PTP-BAS -PTPN13 and Breast Cancer
 9
MIR34A 1p36.22 mir-34, MIRN34A, mir-34a, miRNA34A -MIR34A and Breast Cancer
 9
GSTM3 1p13.3 GST5, GSTB, GTM3, GSTM3-3 -GSTM3 and Breast Cancer
 9
LIG4 13q33.3 LIG4S -LIG4 and Breast Cancer
 9
AGO2 8q24.3 PPD, Q10, CASC7, EIF2C2, LINC00980 -EIF2C2 and Breast Cancer
 9
SOCS2 12q22 CIS2, SSI2, Cish2, SSI-2, SOCS-2, STATI2 -SOCS2 and Breast Cancer
 9
MALL 2q13 BENE -MALL and Breast Cancer
 9
SKP1 5q31.1 OCP2, p19A, EMC19, SKP1A, OCP-II, TCEB1L -SKP1 and Breast Cancer
 9
PTPRC 1q31.3-q32.1 LCA, LY5, B220, CD45, L-CA, T200, CD45R, GP180 -PTPRC and Breast Cancer
 9
FGF8 10q24.32 HH6, AIGF, KAL6, FGF-8, HBGF-8 -FGF8 and Breast Cancer
 9
SPHK1 17q25.1 SPHK -SPHK1 and Breast Cancer
 9
RICTOR 5p13.1 PIA, AVO3, hAVO3 -RICTOR and Breast Cancer
 9
IL1B 2q14 IL-1, IL1F2, IL1-BETA -IL1B and Breast Cancer
 9
SUZ12 17q11.2 CHET9, JJAZ1 -SUZ12 and Breast Cancer
 9
IL13 5q31.1 P600, IL-13 -IL13 and Breast Cancer
 9
IGFBP2 2q35 IBP2, IGF-BP53 -IGFBP2 and Breast Cancer
 9
CCNA1 13q13.3 CT146 -CCNA1 and Breast Cancer
 9
MICA 6p21.33 MIC-A, PERB11.1 -MICA and Breast Cancer
 9
BNIP3L 8p21.2 NIX, BNIP3a -BNIP3L and Breast Cancer
 9
AKR1C2 10p15.1 DD, DD2, TDD, BABP, DD-2, DDH2, HBAB, HAKRD, MCDR2, SRXY8, DD/BABP, AKR1C-pseudo -AKR1C2 and Breast Cancer
 9
BUB1B 15q15.1 MVA1, SSK1, BUBR1, Bub1A, MAD3L, hBUBR1, BUB1beta -BUB1B and Breast Cancer
 9
PCGF2 17q12 MEL-18, RNF110, ZNF144 -PCGF2 and Breast Cancer
 9
KDM6A Xp11.3 UTX, KABUK2, bA386N14.2 -KDM6A and Breast Cancer
 9
POT1 7q31.33 GLM9, CMM10, HPOT1 -POT1 and Breast Cancer
 9
MSX2 5q35.2 FPP, MSH, PFM, CRS2, HOX8, PFM1 -MSX2 and Breast Cancer
 8
MIR10A 17q21.32 MIRN10A, mir-10a, miRNA10A, hsa-mir-10a -miR-10a and Breast Cancer
 8
GAB2 11q14.1 -GAB2 and Breast Cancer
 8
ATG7 3p25.3 GSA7, APG7L, APG7-LIKE -ATG7 and Breast Cancer
 8
CASP10 2q33-q34 MCH4, ALPS2, FLICE2 -CASP10 and Breast Cancer
 8
CASP1 11q22.3 ICE, P45, IL1BC -CASP1 and Breast Cancer
 8
HMMR 5q34 CD168, IHABP, RHAMM -HMMR and Breast Cancer
 8
FGF10 5p12 -FGF10 and Breast Cancer
 8
IGFBP4 17q21.2 BP-4, IBP4, IGFBP-4, HT29-IGFBP -IGFBP4 and Breast Cancer
 8
IL15 4q31.21 IL-15 -IL15 and Breast Cancer
 8
CUL1 7q36.1 -CUL1 and Breast Cancer
 8
EFNB2 13q33.3 HTKL, EPLG5, Htk-L, LERK5 -EFNB2 expression in Breast Cancer
 8
EXO1 1q43 HEX1, hExoI -EXO1 and Breast Cancer
 8
CYP11A1 15q24.1 CYP11A, CYPXIA1, P450SCC -CYP11A1 and Breast Cancer
 8
IQGAP1 15q26.1 SAR1, p195, HUMORFA01 -IQGAP1 and Breast Cancer
 8
VCAM1 1p21.2 CD106, INCAM-100 -VCAM1 and Breast Cancer
 8
PTPRQ 12q21.2 DFNB84, DFNB84A, PTPGMC1, R-PTP-Q -PTPRQ and Breast Cancer
 8
NEFL 8p21.2 NFL, NF-L, NF68, CMT1F, CMT2E, PPP1R110 -NEFL and Breast Cancer
 8
TERF2 16q22.1 TRF2, TRBF2 -TERF2 and Breast Cancer
 8
NCOA2 8q13.3 SRC2, TIF2, GRIP1, KAT13C, NCoA-2, bHLHe75 -NCOA2 and Breast Cancer
 8
EPOR 19p13.2 EPO-R -EPOR and Breast Cancer
 8
KLK6 19q13.41 hK6, Bssp, Klk7, SP59, PRSS9, PRSS18 -KLK6 and Breast Cancer
 8
KLK14 19q13.41 KLK-L6 -KLK14 and Breast Cancer
 8
ADAM10 15q21.3 RAK, kuz, AD10, AD18, MADM, CD156c, CDw156, HsT18717 -ADAM10 and Breast Cancer
 8
KRT18 12q13.13 K18, CK-18, CYK18 -KRT18 and Breast Cancer
 8
PTGS1 9q33.2 COX1, COX3, PHS1, PCOX1, PES-1, PGHS1, PTGHS, PGG/HS, PGHS-1 -PTGS1 and Breast Cancer
 8
AKR1C1 10p15.1 C9, DD1, DDH, DDH1, H-37, HBAB, MBAB, HAKRC, DD1/DD2, 2-ALPHA-HSD, 20-ALPHA-HSD -AKR1C1 and Breast Cancer
 8
SUMO1 2q33 DAP1, GMP1, PIC1, SMT3, UBL1, OFC10, SENP2, SMT3C, SMT3H3 -SUMO1 and Breast Cancer
 8
ATF2 2q32 HB16, CREB2, TREB7, CREB-2, CRE-BP1 -ATF2 and Breast Cancer
 8
TLR2 4q31.3 TIL4, CD282 -TLR2 and Breast Cancer
 8
CXCR2 2q35 CD182, IL8R2, IL8RA, IL8RB, CMKAR2, CDw128b -CXCR2 and Breast Cancer
 8
TEP1 14q11.2 TP1, TLP1, p240, TROVE1, VAULT2 -TEP1 and Breast Cancer
 8
CBFA2T3 16q24.3 ETO2, MTG16, MTGR2, ZMYND4, RUNX1T3 -CBFA2T3 and Breast Cancer
 8
WNT4 1p36.12 WNT-4, SERKAL -WNT4 and Breast Cancer
 8
CLDN7 17p13.1 CLDN-7, CEPTRL2, CPETRL2, Hs.84359, claudin-1 -CLDN7 and Breast Cancer
 8
SOX11 2p25 MRD27 -SOX11 and Breast Cancer
 8
BIN1 2q14 AMPH2, AMPHL, SH3P9 -BIN1 and Breast Cancer
 8
FLT4 5q35.3 PCL, FLT-4, FLT41, LMPH1A, VEGFR3, VEGFR-3 -FLT4 and Breast Cancer
 8
LOXL2 8p21.3 LOR, LOR2, WS9-14 -LOXL2 and Breast Cancer
 8
KLK5 19q13.41 SCTE, KLKL2, KLK-L2 -KLK5 and Breast Cancer
 8
SULF2 20q13.12 HSULF-2 -SULF2 and Breast Cancer
 8
WISP1 8q24.22 CCN4, WISP1c, WISP1i, WISP1tc -WISP1 and Breast Cancer
 8
S100P 4p16.1 MIG9 -S100P and Breast Cancer
 8
DDR1 6p21.33 CAK, DDR, NEP, HGK2, PTK3, RTK6, TRKE, CD167, EDDR1, MCK10, NTRK4, PTK3A -DDR1 and Breast Cancer
 8
CRY2 11p11.2 HCRY2, PHLL2 -CRY2 and Breast Cancer
 8
BUB3 10q26.13 BUB3L, hBUB3 -BUB3 and Breast Cancer
 8
PER3 1p36.23 GIG13, FASPS3 -PER3 and Breast Cancer
 8
SIN3A 15q24.2 WITKOS -SIN3A and Breast Cancer
 8
HEY1 8q21.13 CHF2, OAF1, HERP2, HESR1, HRT-1, hHRT1, BHLHb31 -HEY1 and Breast Cancer
 8
WNT10B 12q13.12 SHFM6, STHAG8, WNT-12 -WNT10B and Breast Cancer
 8
ROCK1 18q11.1 ROCK-I, P160ROCK -ROCK1 and Breast Cancer
 8
NEDD9 6p24.2 CAS2, CASL, HEF1, CAS-L, CASS2 -NEDD9 and Breast Cancer
 8
NQO2 6p25.2 QR2, DHQV, DIA6, NMOR2 -NQO2 and Breast Cancer
 8
MELK 9p13.2 HPK38 -MELK and Breast Cancer
 8
PON1 7q21.3 ESA, PON, MVCD5 -PON1 and Breast Cancer
 8
TJP1 15q13.1 ZO-1 -TJP1 and Breast Cancer
 8
EREG 4q13.3 ER, Ep, EPR -EREG and Breast Cancer
 8
TFPI 2q32 EPI, TFI, LACI, TFPI1 -TFPI and Breast Cancer
 8
CA12 15q22.2 CAXII, CA-XII, T18816, HsT18816 -CA12 and Breast Cancer
 8
TNFSF15 9q32 TL1, TL1A, VEGI, TNLG1B, VEGI192A -TNFSF15 and Breast Cancer
 8
MAML1 5q35.3 Mam1, Mam-1 -MAML1 and Breast Cancer
 8
TRADD 16q22.1 Hs.89862 -TRADD and Breast Cancer
 7
ARNTL 11p15.3 TIC, JAP3, MOP3, BMAL1, PASD3, BMAL1c, bHLHe5 -ARNTL and Breast Cancer
 7
BMPR2 2q33-q34 BMR2, PPH1, BMPR3, BRK-3, POVD1, T-ALK, BMPR-II -BMPR2 and Breast Cancer
 7
MYH9 22q12.3 MHA, FTNS, EPSTS, BDPLT6, DFNA17, MATINS, NMMHCA, NMHC-II-A, NMMHC-IIA -MYH9 and Breast Cancer
 7
SLIT2 4p15.31 SLIL3, Slit-2 -SLIT2 and Breast Cancer
 7
IL1A 2q14 IL1, IL-1A, IL1F1, IL1-ALPHA -IL1A and Breast Cancer
 7
FCGR2A 1q23.3 CD32, FCG2, FcGR, CD32A, CDw32, FCGR2, IGFR2, FCGR2A1 -FCGR2A and Breast Cancer
 7
TRIO 5p15.2 tgat, MEBAS, MRD44, ARHGEF23 -TRIO and Breast Cancer
 7
MYOD1 11p15.1 PUM, MYF3, MYOD, bHLHc1 -MYOD1 and Breast Cancer
 7
DUSP4 8p12 TYP, HVH2, MKP2, MKP-2 -DUSP4 and Breast Cancer
 7
HSPA8 11q24.1 LAP1, HSC54, HSC70, HSC71, HSP71, HSP73, LAP-1, NIP71, HEL-33, HSPA10, HEL-S-72p -HSPA8 and Breast Cancer
 7
NSD3 8p11.23 KMT3F, KMT3G, WHISTLE, WHSC1L1, pp14328 -WHSC1L1 and Breast Cancer
 7
TFF2 21q22.3 SP, SML1 -TFF2 and Breast Cancer
 7
ANGPTL4 19p13.2 NL2, ARP4, FIAF, HARP, PGAR, HFARP, TGQTL, UNQ171, pp1158 -ANGPTL4 and Breast Cancer
 7
HBEGF 5q31.3 DTR, DTS, DTSF, HEGFL -HBEGF and Breast Cancer
 7
BCAS1 20q13.2 AIBC1, NABC1 -BCAS1 and Breast Cancer
 7
LDHA 11p15.1 LDHM, GSD11, PIG19, HEL-S-133P -LDHA and Breast Cancer
 7
PINX1 8p23.1 LPTL, LPTS -PINX1 and Breast Cancer
 7
CCL21 9p13.3 ECL, SLC, CKb9, TCA4, 6Ckine, SCYA21 -CCL21 and Breast Cancer
 7
PER1 17p13.1 PER, hPER, RIGUI -PER1 and Breast Cancer
 7
ALDH3A1 17p11.2 ALDH3, ALDHIII -ALDH3A1 and Breast Cancer
 7
CD36 7q21.11 FAT, GP4, GP3B, GPIV, CHDS7, PASIV, SCARB3, BDPLT10 -CD36 and Breast Cancer
 7
PAEP 9q34.3 GD, GdA, GdF, GdS, PEP, PAEG, PP14 -PAEP and Breast Cancer
 7
NR4A1 12q13 HMR, N10, TR3, NP10, GFRP1, NAK-1, NGFIB, NUR77 -NR4A1 and Breast Cancer
 7
HDAC4 2q37.3 HD4, AHO3, BDMR, HDACA, HA6116, HDAC-4, HDAC-A -HDAC4 and Breast Cancer
 7
ADIPOQ 3q27 ACDC, ADPN, APM1, APM-1, GBP28, ACRP30, ADIPQTL1 -ADIPOQ and Breast Cancer
 7
CEBPB 20q13.13 TCF5, IL6DBP, NF-IL6, C/EBP-beta -CEBPB and Breast Cancer
 7
FLNA Xq28 FLN, FMD, MNS, OPD, ABPX, CSBS, CVD1, FGS2, FLN1, NHBP, OPD1, OPD2, XLVD, XMVD, FLN-A, ABP-280 -FLNA and Breast Cancer
 7
STC1 8p21.2 STC -STC1 and Breast Cancer
 7
FOSB 19q13.32 AP-1, G0S3, GOS3, GOSB -FOSB and Breast Cancer
 7
HOXA10 7p15.2 PL, HOX1, HOX1H, HOX1.8 -HOXA10 and Breast Cancer
 7
EGLN1 1q42.2 HPH2, PHD2, SM20, ECYT3, HALAH, HPH-2, HIFPH2, ZMYND6, C1orf12, HIF-PH2 -EGLN1 and Breast Cancer
 7
WNT2 7q31.2 IRP, INT1L1 -WNT2 and Breast Cancer
 7
RAD54L 1p34.1 HR54, hHR54, RAD54A, hRAD54 -RAD54L and Breast Cancer
 7
MAP2K2 19p13.3 CFC4, MEK2, MKK2, MAPKK2, PRKMK2 -MAP2K2 and Breast Cancer
 7
LARS 5q32 LRS, LEUS, LFIS, ILFS1, LARS1, LEURS, PIG44, RNTLS, HSPC192, hr025Cl -LARS and Breast Cancer
 7
FOSL1 11q13.1 FRA, FRA1, fra-1 -FOSL1 and Breast Cancer
 7
EEF1A2 20q13.33 HS1, STN, EF1A, STNL, MRD38, EEF1AL, EIEE33, EF-1-alpha-2 -EEF1A2 and Breast Cancer
 7
NUMB 14q24.2-q24.3 S171, C14orf41, c14_5527 -NUMB and Breast Cancer
 7
ADAM17 2p25 CSVP, TACE, NISBD, ADAM18, CD156B, NISBD1 -ADAM17 and Breast Cancer
 7
CDK7 5q13.2 CAK, CAK1, HCAK, MO15, STK1, CDKN7, p39MO15 -CDK7 and Breast Cancer
 7
DRD2 11q23.2 D2R, D2DR -DRD2 and Breast Cancer
 7
CYBA 16q24.2 p22-PHOX -CYBA and Breast Cancer
 7
ARL11 13q14.2 ARLTS1 -ARL11 and Breast Cancer
 7
TP53BP2 1q41 BBP, 53BP2, ASPP2, P53BP2, PPP1R13A -TP53BP2 and Breast Cancer
 7
TRAF6 11p12 RNF85, MGC:3310 -TRAF6 and Breast Cancer
 7
UGT2B15 4q13.2 HLUG4, UGT2B8, UDPGTH3, UDPGT 2B8, UDPGT2B15 -UGT2B15 and Breast Cancer
 7
IL2 4q27 IL-2, TCGF, lymphokine -IL2 and Breast Cancer
 7
TLR1 4p14 TIL, CD281, rsc786, TIL. LPRS5 -TLR1 and Breast Cancer
 7
MX1 21q22.3 MX, MxA, IFI78, IFI-78K -MX1 and Breast Cancer
 7
GATA4 8p23.1 TOF, ASD2, VSD1, TACHD -GATA4 and Breast Cancer
 7
PYGM 11q13.1 -PYGM and Breast Cancer
 7
CTBP1 4p16.3 BARS -CTBP1 and Breast Cancer
 7
CKS1B 1q21.3 CKS1, ckshs1, PNAS-16, PNAS-18 -CKS1B and Breast Cancer
 7
BANP 16q24.2 BEND1, SMAR1, SMARBP1 -BANP and Breast Cancer
 7
TNFAIP3 6q23.3 A20, AISBL, OTUD7C, TNFA1P2 -TNFAIP3 and Breast Cancer
 7
PARK7 1p36.23 DJ1, DJ-1, GATD2, HEL-S-67p -PARK7 and Breast Cancer
 7
ADIPOR2 12p13.31 PAQR2, ACDCR2 -ADIPOR2 and Breast Cancer
 7
E2F5 8q21.2 E2F-5 -E2F5 and Breast Cancer
 7
CCR2 3p21.31 CKR2, CCR-2, CCR2A, CCR2B, CD192, CKR2A, CKR2B, CMKBR2, MCP-1-R, CC-CKR-2 -CCR2 and Breast Cancer
 6
EBAG9 8q23.2 EB9, PDAF -EBAG9 and Breast Cancer
 6
LYVE1 11p15.4 HAR, XLKD1, LYVE-1, CRSBP-1 -LYVE1 and Breast Cancer
 6
RASSF2 20p13 CENP-34, RASFADIN -RASSF2 and Breast Cancer
 6
CCL19 9p13.3 ELC, CKb11, MIP3B, MIP-3b, SCYA19 -CCL19 and Breast Cancer
 6
SHMT1 17p11.2 SHMT, CSHMT -SHMT1 and Breast Cancer
 6
ADH1B 4q23 ADH2, HEL-S-117 -ADH1B and Breast Cancer
 6
LTA 6p21.33 LT, TNFB, TNFSF1, TNLG1E -LTA and Breast Cancer
 6
MVP 16p11.2 LRP, VAULT1 -MVP and Breast Cancer
 6
CTSL 9q21.33 MEP, CATL, CTSL1 -CTSL1 and Breast Cancer
 6
SCRIB 8q24.3 CRIB1, SCRB1, SCRIB1, Vartul -SCRIB and Breast Cancer
 6
MAGEA4 Xq28 CT1.4, MAGE4, MAGE4A, MAGE4B, MAGE-41, MAGE-X2 -MAGEA4 and Breast Cancer
 6
FGF19 11q13.3 -FGF19 and Breast Cancer
 6
POU2F1 1q24.2 OCT1, OTF1, oct-1B -POU2F1 and Breast Cancer
 6
FGF7 15q21.2 KGF, HBGF-7 -FGF7 and Breast Cancer
 6
CUL3 2q36.2 CUL-3, PHA2E -CUL3 and Breast Cancer
 6
STRADA 17q23.3 LYK5, PMSE, Stlk, STRAD, NY-BR-96 -STRADA and Breast Cancer
 6
FSCN1 7p22.1 HSN, SNL, p55, FAN1 -FSCN1 and Breast Cancer
 6
TNFRSF10C 8p21.3 LIT, DCR1, TRID, CD263, TRAILR3, TRAIL-R3, DCR1-TNFR -TNFRSF10C and Breast Cancer
 6
NBR1 17q21.31 IAI3B, M17S2, MIG19, 1A1-3B -NBR1 and Breast Cancer
 6
PRDM2 1p36.21 RIZ, KMT8, RIZ1, RIZ2, KMT8A, MTB-ZF, HUMHOXY1 -PRDM2 and Breast Cancer
 6
USF1 1q23.3 UEF, FCHL, MLTF, FCHL1, MLTFI, HYPLIP1, bHLHb11 -USF1 and Breast Cancer
 6
PRKCD 3p21.1 MAY1, PKCD, ALPS3, CVID9, nPKC-delta -PRKCD and Breast Cancer
 6
NUMA1 11q13.4 NUMA, NMP-22 -NUMA1 and Breast Cancer
 6
SMYD3 1q44 KMT3E, ZMYND1, ZNFN3A1, bA74P14.1 -SMYD3 and Breast Cancer
 6
DMBT1 10q26.13 SAG, GP340, SALSA, muclin -DMBT1 and Breast Cancer
 6
PLAT 8p11.21 TPA, T-PA -PLAT and Breast Cancer
 6
TANK 2q24.2 ITRAF, TRAF2, I-TRAF -TANK and Breast Cancer
 6
CMBL 5p15.2 JS-1 -CMBL and Breast Cancer
 6
NDRG2 14q11.2 SYLD -NDRG2 and Breast Cancer
 6
SEMA3B 3p21.31 SemA, SEMA5, SEMAA, semaV, LUCA-1 -SEMA3B and Breast Cancer
 6
TFAP2B 6p12.3 PDA2, AP-2B, AP2-B -TFAP2B and Breast Cancer
 6
MTUS1 8p22 ATBP, ATIP, ICIS, MP44, ATIP3, MTSG1 -MTUS1 and Breast Cancer
 6
ITGA6 2q31.1 CD49f, VLA-6, ITGA6B -ITGA6 and Breast Cancer
 6
CHUK 10q24.31 IKK1, IKKA, IKBKA, TCF16, NFKBIKA, IKK-alpha -CHUK and Breast Cancer
 6
POLD1 19q13.33 CDC2, MDPL, POLD, CRCS10 -POLD1 and Breast Cancer
 6
MCM2 3q21 BM28, CCNL1, CDCL1, cdc19, D3S3194, MITOTIN -MCM2 and Breast Cancer
 6
ABCA1 9q31.1 TGD, ABC1, CERP, ABC-1, HDLDT1 -ABCA1 and Breast Cancer
 6
PMP22 17p12 DSS, CIDP, GAS3, HNPP, CMT1A, CMT1E, GAS-3, Sp110, HMSNIA -PMP22 and Breast Cancer
 6
CCNG2 4q21.1 -CCNG2 and Breast Cancer
 6
BCL2L12 19q13.33 -BCL2L12 and Breast Cancer
 6
DGCR8 22q11.21 Gy1, pasha, DGCRK6, C22orf12 -DGCR8 and Breast Cancer
 6
GSTO2 10q25.1 GSTO 2-2, bA127L20.1 -GSTO2 and Breast Cancer
 6
TACR1 2p12 SPR, NK1R, NKIR, TAC1R -TACR1 and Breast Cancer
 6
PRDX1 1p34.1 PAG, PAGA, PAGB, PRX1, PRXI, MSP23, NKEFA, TDPX2, NKEF-A -PRDX1 and Breast Cancer
 6
DDIT4 10q22.1 Dig2, REDD1, REDD-1 -DDIT4 and Breast Cancer
 6
ITGA4 2q31.3 IA4, CD49D -ITGA4 and Breast Cancer
 6
KRT8 12q13 K8, KO, CK8, CK-8, CYK8, K2C8, CARD2 -KRT8 and Breast Cancer
 6
AGTR2 Xq23 AT2, ATGR2, MRX88 -AGTR2 and Breast Cancer
 6
NRP1 10p11.22 NP1, NRP, BDCA4, CD304, VEGF165R -NRP1 and Breast Cancer
 6
GREM1 15q13.3 DRM, HMPS, MPSH, PIG2, CRAC1, CRCS4, DAND2, HMPS1, IHG-2, DUP15q, C15DUPq, GREMLIN, CKTSF1B1 -GREM1 and Breast Cancer
 6
GSTO1 10q25.1 P28, SPG-R, GSTO 1-1, GSTTLp28, HEL-S-21 -GSTO1 and Breast Cancer
 6
ETV6 12p13.2 TEL, THC5, TEL/ABL Translocation
 -t(12;15)(p13;q25) ETV6-NTRK3 in Breast Cancer
 6
PDPK1 16p13.3 PDK1, PDPK2, PDPK2P, PRO0461 -PDPK1 and Breast Cancer
 6
ROBO1 3p12 SAX3, DUTT1 -ROBO1 and Breast Cancer
 6
ROR1 1p31.3 NTRKR1, dJ537F10.1 -ROR1 and Breast Cancer
 6
SLC19A2 1q24.2 TC1, THT1, TRMA, THMD1, THTR1 -SLC19A2 and Breast Cancer
 6
CHI3L1 1q32.1 GP39, ASRT7, GP-39, YK-40, YKL40, CGP-39, YKL-40, YYL-40, HC-gp39, HCGP-3P, hCGP-39 -CHI3L1 and Breast Cancer
 6
TPM1 15q22.2 CMH3, TMSA, CMD1Y, LVNC9, C15orf13, HEL-S-265, HTM-alpha -TPM1 and Breast Cancer
 6
ST7 7q31.2 HELG, RAY1, SEN4, TSG7, ETS7q, FAM4A, FAM4A1 -ST7 and Breast Cancer
 6
SEPT9 17q25.3 MSF, MSF1, NAPB, SINT1, PNUTL4, SeptD1, AF17q25 -SEPT9 and Breast Cancer
 6
CD163 12p13.3 M130, MM130 -CD163 and Breast Cancer
 6
MAD1L1 7p22.3 MAD1, PIG9, TP53I9, TXBP181 -MAD1L1 and Breast Cancer
 6
HPGD 4q34.1 PGDH, PGDH1, PHOAR1, 15-PGDH, SDR36C1 -HPGD and Breast Cancer
 6
NOD2 16q12.1 CD, ACUG, BLAU, IBD1, YAOS, BLAUS, NLRC2, NOD2B, CARD15, CLR16.3, PSORAS1 -NOD2 and Breast Cancer
 6
PTPRG 3p21-p14 PTPG, HPTPG, RPTPG, R-PTP-GAMMA -PTPRG and Breast Cancer
 6
ATF6 1q23.3 ACHM7, ATF6A -ATF6 and Breast Cancer
 6
FUT4 11q21 LeX, CD15, ELFT, FCT3A, FUTIV, SSEA-1, FUC-TIV -FUT4 and Breast Cancer
 6
PTPRJ 11p11.2 DEP1, SCC1, CD148, HPTPeta, R-PTP-ETA -PTPRJ and Breast Cancer
 6
KISS1R 19p13.3 HH8, CPPB1, GPR54, AXOR12, KISS-1R, HOT7T175 -KISS1R and Breast Cancer
 6
GDNF 5p13.2 ATF, ATF1, ATF2, HSCR3, HFB1-GDNF -GDNF and Breast Cancer
 6
CLDN3 7q11.23 RVP1, HRVP1, C7orf1, CPE-R2, CPETR2 -CLDN3 and Breast Cancer
 6
CEACAM6 19q13.2 NCA, CEAL, CD66c -CEACAM6 and Breast Cancer
 6
PPARGC1A 4p15.2 LEM6, PGC1, PGC1A, PGC-1v, PPARGC1, PGC-1alpha, PGC-1(alpha) -PPARGC1A and Breast Cancer
 6
MMP8 11q22.2 HNC, CLG1, MMP-8, PMNL-CL -MMP8 and Breast Cancer
 6
ACTA2 10q23.31 AAT6, ACTSA, MYMY5 -ACTA2 and Breast Cancer
 6
RAC3 17q25.3 -RAC3 and Breast Cancer
 6
GAS6 13q34 AXSF, AXLLG -GAS6 and Breast Cancer
 6
TNKS 8p23.1 TIN1, ARTD5, PARPL, TINF1, TNKS1, pART5, PARP5A, PARP-5a -TNKS and Breast Cancer
 6
PLA2G4A 1q31.1 GURDP, cPLA2, PLA2G4, cPLA2-alpha -PLA2G4A and Breast Cancer
 6
RBX1 22q13.2 ROC1, RNF75, BA554C12.1 -RBX1 and Breast Cancer
 5
MAPK14 6p21.31 RK, p38, CSBP, EXIP, Mxi2, CSBP1, CSBP2, CSPB1, PRKM14, PRKM15, SAPK2A, p38ALPHA -MAPK14 and Breast Cancer
 5
LRP6 12p13.2 ADCAD2 -LRP6 and Breast Cancer
 5
DKC1 Xq28 DKC, CBF5, DKCX, NAP57, NOLA4, XAP101 -DKC1 and Breast Cancer
 5
LAPTM4B 8q22.1 LC27, LAPTM4beta -LAPTM4B and Breast Cancer
 5
TYRO3 15q15.1 BYK, Dtk, RSE, Rek, Sky, Tif, Etk-2 -TYRO3 and Breast Cancer
 5
DLL4 15q15.1 AOS6, hdelta2 -DLL4 and Breast Cancer
 5
LASP1 17q12 MLN50, Lasp-1 -LASP1 and Breast Cancer
 5
LZTS1 8p21.3 F37, FEZ1 -LZTS1 and Breast Cancer
 5
MTHFD1 14q23.3 MTHFC, MTHFD -MTHFD1 and Breast Cancer
 5
HOXC11 12q13.13 HOX3H -HOXC11 and Breast Cancer
 5
MCM7 7q22.1 MCM2, CDC47, P85MCM, P1CDC47, PNAS146, PPP1R104, P1.1-MCM3 -MCM7 and Breast Cancer
 5
GAB1 4q31.21 -GAB1 and Breast Cancer
 5
ING4 12p13.31 my036, p29ING4 -ING4 and Breast Cancer
 5
KLK4 19q13.41 ARM1, EMSP, PSTS, AI2A1, EMSP1, KLK-L1, PRSS17, kallikrein -KLK4 and Breast Cancer
 5
SULF1 8q13.2-q13.3 SULF-1 -SULF1 and Breast Cancer
 5
DUSP6 12q21.33 HH19, MKP3, PYST1 -DUSP6 and Breast Cancer
 5
SEMA3A 7q21.11 HH16, SemD, COLL1, SEMA1, SEMAD, SEMAL, coll-1, Hsema-I, SEMAIII, Hsema-III -SEMA3A and Breast Cancer
 5
IGFBP7 4q12 AGM, PSF, TAF, FSTL2, IBP-7, MAC25, IGFBP-7, RAMSVPS, IGFBP-7v, IGFBPRP1 -IGFBP7 and Breast Cancer
 5
ALOX5 10q11.21 5-LO, 5LPG, LOG5, 5-LOX -ALOX5 and Breast Cancer
 5
MIRLET7G 3p21.1 LET7G, let-7g, MIRNLET7G, hsa-let-7g -MicroRNA let-7g and Breast Cancer
 5
MAPK3 16p11.2 ERK1, ERT2, ERK-1, PRKM3, P44ERK1, P44MAPK, HS44KDAP, HUMKER1A, p44-ERK1, p44-MAPK -MAPK3 and Breast Cancer
 5
PRAME 22q11.22 MAPE, OIP4, CT130, OIP-4 -PRAME and Breast Cancer
 5
BCL2L2 14q11.2 BCLW, BCL-W, PPP1R51, BCL2-L-2 -BCL2L2 and Breast Cancer
 5
LRP1 12q13.3 APR, LRP, A2MR, CD91, APOER, LRP1A, TGFBR5, IGFBP3R -LRP1 and Breast Cancer
 5
GNRHR 4q13.2 HH7, GRHR, LRHR, LHRHR, GNRHR1 -GNRHR and Breast Cancer
 5
ENO1 1p36.23 NNE, PPH, MPB1, ENO1L1, HEL-S-17 -ENO1 and Breast Cancer
 5
LRIG1 3p14 LIG1, LIG-1 -LRIG1 and Breast Cancer
 5
CXCL9 4q21.1 CMK, MIG, Humig, SCYB9, crg-10 -CXCL9 and Breast Cancer
 5
WNT11 11q13.5 HWNT11 -WNT11 and Breast Cancer
 5
CXCL14 5q31.1 KEC, KS1, BMAC, BRAK, NJAC, MIP2G, MIP-2g, SCYB14 -CXCL14 and Breast Cancer
 5
HIPK2 7q34 PRO0593 -HIPK2 and Breast Cancer
 5
FHL2 2q12.2 DRAL, AAG11, FHL-2, SLIM3, SLIM-3 -FHL2 and Breast Cancer
 5
ADAMTS1 21q21.3 C3-C5, METH1 -ADAMTS1 and Breast Cancer
 5
CASP6 4q25 MCH2 -CASP6 and Breast Cancer
 5
FABP7 6q22.31 MRG, BLBP, FABPB, B-FABP -FABP7 and Breast Cancer
 5
HPSE 4q21.23 HPA, HPA1, HPR1, HSE1, HPSE1 -HPSE and Breast Cancer
 5
RAG2 11p12 RAG-2 -RAG2 and Breast Cancer
 5
TP53INP1 8q22.1 SIP, Teap, p53DINP1, TP53DINP1, TP53INP1A, TP53INP1B -TP53INP1 and Breast Cancer
 5
IMP3 15q24.2 BRMS2, MRPS4, C15orf12 -IMP3 and Breast Cancer
 5
S100A2 1q21.3 CAN19, S100L -S100A2 and Breast Cancer
 5
BTG1 12q21.33 APRO2 -BTG1 and Breast Cancer
 5
KRT14 17q21.2 K14, NFJ, CK14, EBS3, EBS4 -KRT14 and Breast Cancer
 5
HYAL1 3p21.31 MPS9, NAT6, LUCA1, HYAL-1 -HYAL1 and Breast Cancer
 5
CXCL5 4q13.3 SCYB5, ENA-78 -CXCL5 and Breast Cancer
 5
ERCC6 10q11.23 CSB, CKN2, COFS, ARMD5, COFS1, POF11, RAD26, UVSS1 -ERCC6 and Breast Cancer
 5
CASP4 11q22.3 TX, Mih1, ICH-2, Mih1/TX, ICEREL-II, ICE(rel)II -CASP4 and Breast Cancer
 5
MUC5B 11p15.5 MG1, MUC5, MUC9, MUC-5B -MUC5B and Breast Cancer
 5
CXCR1 2q35 C-C, CD128, CD181, CKR-1, IL8R1, IL8RA, CMKAR1, IL8RBA, CDw128a, C-C-CKR-1 -CXCR1 and Breast Cancer
 5
NFATC2 20q13.2 NFAT1, NFATP -NFATC2 and Breast Cancer
 5
APOB 2p24-p23 FLDB, LDLCQ4 -APOB and Breast Cancer
 5
SMARCA2 9p24.3 BRM, SNF2, SWI2, hBRM, NCBRS, Sth1p, BAF190, SNF2L2, SNF2LA, hSNF2a -SMARCA2 and Breast Cancer
 5
SSTR5 16p13.3 SS-5-R -SSTR5 and Breast Cancer
 5
PROX1 1q32.3 -PROX1 and Breast Cancer
 5
BCL3 19q13.32 BCL4, D19S37 -BCL3 and Breast Cancer
 5
TPD52L1 6q22.31 D53 -TPD52L1 and Breast Cancer
 5
CCL20 2q36.3 CKb4, LARC, ST38, MIP3A, Exodus, MIP-3a, SCYA20, MIP-3-alpha -CCL20 and Breast Cancer
 5
TNFRSF10D 8p21.3 DCR2, CD264, TRUNDD, TRAILR4, TRAIL-R4 -TNFRSF10D and Breast Cancer
 5
CXCL16 17p13.2 SRPSOX, CXCLG16, SR-PSOX -CXCL16 and Breast Cancer
 5
TRAF1 9q33.2 EBI6, MGC:10353 -TRAF1 and Breast Cancer
 5
TXNRD1 12q23.3 TR, TR1, TXNR, TRXR1, GRIM-12 -TXNRD1 and Breast Cancer
 5
SSTR1 14q21.1 SS1R, SS1-R, SRIF-2, SS-1-R -SSTR1 and Breast Cancer
 5
RALGDS 9q34.13-q34.2 RGF, RGDS, RalGEF -RALGDS and Breast Cancer
 5
PRRX1 1q24.2 PMX1, PRX1, AGOTC, PHOX1, PRX-1 -PRRX1 and Breast Cancer
 5
POU1F1 3p11 PIT1, CPHD1, GHF-1, Pit-1, POU1F1a -POU1F1 and Breast Cancer
 5
RARRES3 11q12.3 RIG1, TIG3, HRSL4, HRASLS4, PLA1/2-3 -RARRES3 and Breast Cancer
 5
FRZB 2q32.1 FRE, OS1, FZRB, hFIZ, FRITZ, FRP-3, FRZB1, SFRP3, SRFP3, FRZB-1, FRZB-PEN -FRZB and Breast Cancer
 5
MTSS1 8q24.13 MIM, MIMA, MIMB -MTSS1 and Breast Cancer
 5
MIRLET7E 19q13.41 LET7E, let-7e, MIRNLET7E, hsa-let-7e -None and Breast Cancer
 5
NOX1 Xq22.1 MOX1, NOH1, NOH-1, GP91-2 -NOX1 and Breast Cancer
 5
CD276 15q24.1 B7H3, B7-H3, B7RP-2, 4Ig-B7-H3 -CD276 and Breast Cancer
 5
DAB2IP 9q33.2 AIP1, AIP-1, AF9Q34, DIP1/2 -DAB2IP and Breast Cancer
 5
SAT2 17p13.1 SSAT2 -SAT2 and Breast Cancer
 5
LDLR 19p13.2 FH, FHC, LDLCQ2 -LDLR and Breast Cancer
 5
SPRY1 4q28.1 hSPRY1 -SPRY1 and Breast Cancer
 5
PPP2R1B 11q23.1 PR65B, PP2A-Abeta -PPP2R1B and Breast Cancer
 5
ETV5 3q27.2 ERM -ETV5 and Breast Cancer
 5
ST14 11q24.3 HAI, MTSP1, SNC19, ARCI11, MT-SP1, PRSS14, TADG15, TMPRSS14 -ST14 and Breast Cancer
 5
KLLN 10q23.31 CWS4, KILLIN -KLLN and Breast Cancer
 5
SKIL 3q26 SNO, SnoA, SnoI, SnoN -SKIL and Breast Cancer
 5
EGLN3 14q13.1 PHD3, HIFPH3, HIFP4H3 -EGLN3 and Breast Cancer
 5
SFRP5 10q24.2 SARP3 -SFRP5 and Breast Cancer
 5
BMPR1B 4q22.3 ALK6, AMDD, BDA2, ALK-6, BDA1D, CDw293 -BMPR1B and Breast Cancer
 5
AIFM1 Xq26.1 AIF, AUNX1, CMT2D, CMTX4, COWCK, DFNX5, NADMR, NAMSD, PDCD8, COXPD6 -AIFM1 and Breast Cancer
 5
WARS 14q32.2 IFI53, IFP53, GAMMA-2 -WARS and Breast Cancer
 5
SOX18 20q13.33 HLTS, HLTRS -SOX18 and Breast Cancer
 5
TFRC 3q29 T9, TR, TFR, p90, CD71, TFR1, TRFR, IMD46 -TFRC and Breast Cancer
 5
STAT2 12q13.3 P113, IMD44, ISGF-3, STAT113 -STAT2 and Breast Cancer
 5
PVT1 8q24.21 MYC, LINC00079, NCRNA00079, onco-lncRNA-100 -PVT1 and Breast Cancer
 5
TAGLN 11q23.3 SM22, SMCC, TAGLN1, WS3-10 -TAGLN and Breast Cancer
 5
AMFR 16q13 GP78, RNF45 -AMFR and Breast Cancer
 5
PTMS 12p13 ParaT -PTMS and Breast Cancer
 5
COL4A2 13q34 ICH, POREN2 -COL4A2 and Breast Cancer
 5
CCR4 3p24 CKR4, K5-5, CD194, CMKBR4, ChemR13, CC-CKR-4, HGCN:14099 -CCR4 and Breast Cancer
 5
PPIA 7p13 CYPA, CYPH, HEL-S-69p -PPIA and Breast Cancer
 5
IER3 6p21.3 DIF2, IEX1, PRG1, DIF-2, GLY96, IEX-1, IEX-1L -IER3 and Breast Cancer
 5
CXCR5 11q23.3 BLR1, CD185, MDR15 -CXCR5 and Breast Cancer
 5
RECQL4 8q24.3 RECQ4 -RECQL4 and Breast Cancer
 5
SETD2 3p21.31 LLS, HYPB, SET2, HIF-1, HIP-1, KMT3A, HBP231, HSPC069, p231HBP -SETD2 and Breast Cancer
 5
CALU 7q32.1 -CALU and Breast Cancer
 5
CD151 11p15.5 GP27, MER2, RAPH, SFA1, PETA-3, TSPAN24 -CD151 and Breast Cancer
 5
TBK1 12q14.1 NAK, T2K -TBK1 and Breast Cancer
 5
CDK5 7q36.1 LIS7, PSSALRE -CDK5 and Breast Cancer
 5
HYAL2 3p21.3 LUCA2 -HYAL2 and Breast Cancer
 4
CX3CL1 16q21 NTN, NTT, CXC3, CXC3C, SCYD1, ABCD-3, C3Xkine, fractalkine, neurotactin -CX3CL1 and Breast Cancer
 4
CASP5 11q22.3 ICH-3, ICEREL-III, ICE(rel)III -CASP5 and Breast Cancer
 4
CDK9 9q34.11 TAK, C-2k, CTK1, CDC2L4, PITALRE -CDK9 and Breast Cancer
 4
KDM4C 9p24.1 GASC1, JHDM3C, JMJD2C, TDRD14C -KDM4C and Breast Cancer
 4
HSD3B1 1p12 HSD3B, HSDB3, HSDB3A, SDR11E1, 3BETAHSD -HSD3B1 and Breast Cancer
 4
MYCN 2p24.3 NMYC, ODED, MODED, N-myc, bHLHe37 -MYCN and Breast Cancer
 4
SMPD1 11p15.4 ASM, NPD, ASMASE -SMPD1 and Breast Cancer
 4
MEST 7q32.2 PEG1 -MEST and Breast Cancer
 4
TBX21 17q21.32 TBET, T-PET, T-bet, TBLYM -TBX21 and Breast Cancer
 4
MINA 3q11.2 ROX, MDIG, NO52, MINA53 -MINA and Breast Cancer
 4
ARID4A 14q23.1 RBP1, RBBP1, RBP-1, RBBP-1 -ARID4A and Breast Cancer
 4
CXCL11 4q21.1 IP9, H174, IP-9, b-R1, I-TAC, SCYB11, SCYB9B -CXCL11 and Breast Cancer
 4
MIRLET7I 12q14.1 LET7I, let-7i, MIRNLET7I, hsa-let-7i -None and Breast Cancer
 4
SLCO1B3 12p12.2 LST3, HBLRR, LST-2, OATP8, OATP-8, OATP1B3, SLC21A8, LST-3TM13 -SLCO1B3 and Breast Cancer
 4
HOXC6 12q13.13 CP25, HOX3, HOX3C, HHO.C8 -HOXC6 and Breast Cancer
 4
IFITM1 11p15.5 9-27, CD225, IFI17, LEU13, DSPA2a -IFITM1 and Breast Cancer
 4
RBP1 3q23 CRBP, RBPC, CRBP1, CRBPI, CRABP-I -RBP1 and Breast Cancer
 4
NOX4 11q14.3 KOX, KOX-1, RENOX -NOX4 and Breast Cancer
 4
CTSB 8p23.1 APPS, CPSB -CTSB and Breast Cancer
 4
NSD1 5q35.3 STO, KMT3B, SOTOS, ARA267, SOTOS1 -NSD1 and Breast Cancer
 4
SLCO1B1 12p12.1 LST1, HBLRR, LST-1, OATP2, OATPC, OATP-C, OATP1B1, SLC21A6 -SLCO1B1 and Breast Cancer
 4
GADD45B 19p13.3 MYD118, GADD45BETA -GADD45B and Breast Cancer
 4
GJB2 13q12.11 HID, KID, PPK, CX26, DFNA3, DFNB1, NSRD1, DFNA3A, DFNB1A -GJB2 and Breast Cancer
 4
BCL11A 2p16.1 EVI9, CTIP1, ZNF856, HBFQTL5, BCL11A-L, BCL11A-S, BCL11a-M, BCL11A-XL Amplification
Overexpression
 -BCL11A Overexpression and Amplification Breast Cancer
 4
MUC16 19p13.2 CA125 -MUC16 and Breast Cancer
 4
AVPR1A 12q14.2 V1aR, AVPR1, AVPR V1a -AVPR1A and Breast Cancer
 4
MT2A 16q13 MT2 -MT2A and Breast Cancer
 4
THRB 3p24.2 GRTH, PRTH, THR1, ERBA2, NR1A2, THRB1, THRB2, C-ERBA-2, C-ERBA-BETA -THRB and Breast Cancer
 4
FMR1 Xq27.3 POF, FMRP, POF1, FRAXA -FMR1 and Breast Cancer
 4
PLAGL1 6q24.2 ZAC, LOT1, ZAC1 -PLAGL1 and Breast Cancer
 4
THRA 17q21.1 AR7, EAR7, ERBA, CHNG6, ERBA1, NR1A1, THRA1, THRA2, ERB-T-1, c-ERBA-1 -THRA and Breast Cancer
 4
PRKCDBP 11p15.4 SRBC, HSRBC, CAVIN3, cavin-3 -PRKCDBP and Breast Cancer
 4
CD69 12p13.31 AIM, EA1, MLR-3, CLEC2C, GP32/28, BL-AC/P26 -CD69 and Breast Cancer
 4
FER 5q21.3 TYK3, PPP1R74, p94-Fer -FER and Breast Cancer
 4
KIAA1524 3q13.13 p90, CIP2A -KIAA1524 and Breast Cancer
 4
TDGF1 3p21.31 CR, CRGF, CRIPTO -TDGF1 and Breast Cancer
 4
SDC4 20q13.12 SYND4 -SDC4 and Breast Cancer
 4
IL24 1q32.1 C49A, FISP, MDA7, MOB5, ST16, IL10B -IL24 and Breast Cancer
 4
GMNN 6p22.3 Gem -GMNN and Breast Cancer
 4
FABP5 8q21.13 EFABP, KFABP, E-FABP, PAFABP, PA-FABP -FABP5 and Breast Cancer
 4
MME 3q25.2 NEP, SFE, CD10, CALLA, CMT2T, SCA43 -MME and Breast Cancer
 4
SRD5A1 5p15.31 S5AR 1 -SRD5A1 and Breast Cancer
 4
GRASP 12q13.13 TAMALIN -GRASP and Breast Cancer
 4
OCLN 5q13.2 BLCPMG, PPP1R115 -OCLN and Breast Cancer
 4
RAG1 11p12 RAG-1, RNF74 -RAG1 and Breast Cancer
 4
GATA5 20q13.33 CHTD5, GATAS, bB379O24.1 -GATA5 and Breast Cancer
 4
PHIP 6q14.1 ndrp, BRWD2, WDR11, DCAF14 -PHIP and Breast Cancer
 4
GRM1 6q24 MGLU1, GPRC1A, MGLUR1, SCAR13, PPP1R85 -GRM1 and Breast Cancer
 4
CCNG1 5q34 CCNG -CCNG1 and Breast Cancer
 4
ANO1 11q13.3 DOG1, TAOS2, ORAOV2, TMEM16A -ANO1 and Breast Cancer
 4
GNL3 3p21.1 NS, E2IG3, NNP47, C77032 -GNL3 and Breast Cancer
 4
RAD17 5q13.2 CCYC, R24L, RAD24, HRAD17, RAD17SP -RAD17 and Breast Cancer
 4
NOV 8q24.12 CCN3, NOVh, IBP-9, IGFBP9, IGFBP-9 -NOV and Breast Cancer
 4
ESPL1 12q13.13 ESP1, SEPA -ESPL1 and Breast Cancer
 4
GZMB 14q12 C11, HLP, CCPI, CGL1, CSPB, SECT, CGL-1, CSP-B, CTLA1, CTSGL1 -GZMB and Breast Cancer
 4
LRP5 11q13.2 HBM, LR3, OPS, EVR1, EVR4, LRP7, OPPG, BMND1, LRP-5, OPTA1, VBCH2 -LRP5 and Breast Cancer
 4
MMP10 11q22.2 SL-2, STMY2 -MMP10 and Breast Cancer
 4
ATP7A Xq21.1 MK, MNK, DSMAX, SMAX3 -ATP7A and Breast Cancer
 4
CARS 11p15.4 CARS1, CYSRS, MGC:11246 -CARS and Breast Cancer
 4
HTATIP2 11p15.1 CC3, TIP30, SDR44U1 -HTATIP2 and Breast Cancer
 4
BAGE 21p11.1 BAGE1, CT2.1 -BAGE and Breast Cancer
 4
TRIM24 7q33-q34 PTC6, TF1A, TIF1, RNF82, TIF1A, hTIF1, TIF1ALPHA -TRIM24 and Breast Cancer
 4
CD59 11p13 1F5, EJ16, EJ30, EL32, G344, MIN1, MIN2, MIN3, MIRL, HRF20, MACIF, MEM43, MIC11, MSK21, 16.3A5, HRF-20, MAC-IP, p18-20 -CD59 and Breast Cancer
 4
SNRPN 15q11.2 SMN, PWCR, SM-D, sm-N, RT-LI, HCERN3, SNRNP-N, SNURF-SNRPN -SNRPN and Breast Cancer
 4
AQP1 7p14.3 CO, CHIP28, AQP-CHIP -AQP1 and Breast Cancer
 4
STIM1 11p15.4 GOK, TAM, TAM1, IMD10, STRMK, D11S4896E -STIM1 and Breast Cancer
 4
CCL3 17q12 MIP1A, SCYA3, G0S19-1, LD78ALPHA, MIP-1-alpha -CCL3 and Breast Cancer
 4
RAC2 22q13.1 Gx, EN-7, HSPC022, p21-Rac2 -RAC2 and Breast Cancer
 4
EPB41L3 18p11.31 4.1B, DAL1, DAL-1 -EPB41L3 and Breast Cancer
 4
ARHGDIB 12p12.3 D4, GDIA2, GDID4, LYGDI, Ly-GDI, RAP1GN1, RhoGDI2 -ARHGDIB and Breast Cancer
 4
CCL22 16q21 MDC, ABCD-1, SCYA22, STCP-1, DC/B-CK, A-152E5.1 -CCL22 and Breast Cancer
 4
RNASEL 1q25.3 RNS4, PRCA1 -RNASEL and Breast Cancer
 4
AKAP9 7q21.2 LQT11, PRKA9, AKAP-9, CG-NAP, YOTIAO, AKAP350, AKAP450, PPP1R45, HYPERION, MU-RMS-40.16A -AKAP9 and Breast Cancer
 4
MAGEB2 Xp21.2 DAM6, CT3.2, MAGE-XP-2 -MAGEB2 and Breast Cancer
 4
CRY1 12q23.3 PHLL1 -CRY1 and Breast Cancer
 4
HAS1 19q13.41 HAS -HAS1 and Breast Cancer
 4
IRAK2 3p25.3 IRAK-2 -IRAK2 and Breast Cancer
 4
DEC1 9q33.1 CTS9 -DEC1 and Breast Cancer
 4
MIRLET7D 9q22.32 LET7D, let-7d, MIRNLET7D, hsa-let-7d -None and Breast Cancer
 4
FGR 1p35.3 SRC2, c-fgr, c-src2, p55-Fgr, p58-Fgr, p55c-fgr, p58c-fgr -FGR and Breast Cancer
 4
RACK1 5q35.3 H12.3, HLC-7, PIG21, GNB2L1, Gnb2-rs1 -GNB2L1 and Breast Cancer
 4
MUC3A 7q22.1 MUC3, MUC-3A -MUC3A and Breast Cancer
 3
SGK1 6q23 SGK -SGK1 and Breast Cancer
 3
IL4R 16p12.1 CD124, IL4RA, IL-4RA -IL4R and Breast Cancer
 3
ANGPT1 8q23.1 AGP1, AGPT, ANG1 -ANGPT1 and Breast Cancer
 3
CCNC 6q21 CycC -CCNC and Breast Cancer
 3
POLI 18q21.2 RAD30B, RAD3OB -POLI and Breast Cancer
 3
KAT5 11q13.1 TIP, ESA1, PLIP, TIP60, cPLA2, HTATIP, ZC2HC5, HTATIP1 -KAT5 and Breast Cancer
 3
IL23R 1p31.3 -IL23R and Breast Cancer
 3
MCM5 22q12.3 CDC46, MGORS8, P1-CDC46 -MCM5 and Breast Cancer
 3
PDLIM4 5q31.1 RIL -PDLIM4 and Breast Cancer
 3
CDCP1 3p21.31 CD318, TRASK, SIMA135 -CDCP1 and Breast Cancer
 3
USP7 16p13.2 TEF1, HAUSP -USP7 and Breast Cancer
 3
BOLL 2q33 BOULE -BOLL and Breast Cancer
 3
UCP2 11q13.4 UCPH, BMIQ4, SLC25A8 -UCP2 and Breast Cancer
 3
ZBTB7A 19p13.3 LRF, FBI1, FBI-1, TIP21, ZBTB7, ZNF857A, pokemon -ZBTB7A and Breast Cancer
 3
MIR124-1 8p23.1 MIR124A, MIR124A1, MIRN124-1, MIRN124A1, mir-124-1 -microRNA 124-1 and Breast Cancer
 3
THY1 11q23.3 CD90, CDw90 -THY1 and Breast Cancer
 3
SLC5A8 12q23.1-q23.2 AIT, SMCT, SMCT1 -SLC5A8 and Breast Cancer
 3
CD1D 1q23.1 R3, CD1A, R3G1 -CD1D and Breast Cancer
 3
CTCFL 20q13.31 CT27, BORIS, CTCF-T, HMGB1L1, dJ579F20.2 -CTCFL and Breast Cancer
 3
MAP2K6 17q24.3 MEK6, MKK6, MAPKK6, PRKMK6, SAPKK3, SAPKK-3 -MAP2K6 and Breast Cancer
 3
NOTO 2p13.2 -NOTO and Breast Cancer
 3
RRM2B 8q22.3 P53R2, MTDPS8A, MTDPS8B -RRM2B and Breast Cancer
 3
STK4 20q13.12 KRS2, MST1, YSK3 -STK4 and Breast Cancer
 3
HRK 12q24.22 DP5, HARAKIRI -HRK and Breast Cancer
 3
IL32 16p13.3 NK4, TAIF, TAIFa, TAIFb, TAIFc, TAIFd, IL-32beta, IL-32alpha, IL-32delta, IL-32gamma -IL32 and Breast Cancer
 3
EPHA5 4q13.1-q13.2 EK7, CEK7, EHK1, HEK7, EHK-1, TYRO4 -EPHA5 and Breast Cancer
 3
MAP3K5 6q22.33 ASK1, MEKK5, MAPKKK5 -MAP3K5 and Breast Cancer
 3
UGT2B17 4q13.2 BMND12, UDPGT2B17 -UGT2B17 and Breast Cancer
 3
POLB 8p11.21 -POLB and Breast Cancer
 3
NFATC1 18q23 NFAT2, NFATc, NF-ATC, NF-ATc1.2 -NFATC1 and Breast Cancer
 3
IRF7 11p15.5 IMD39, IRF7A, IRF7B, IRF7C, IRF7H, IRF-7H -IRF7 and Breast Cancer
 3
PITX1 5q31.1 BFT, CCF, POTX, PTX1, LBNBG -PITX1 and Breast Cancer
 3
TLE1 9q21.32 ESG, ESG1, GRG1 -TLE1 and Breast Cancer
 3
TLR6 4p14 CD286 -TLR6 and Breast Cancer
 3
CKS2 9q22.2 CKSHS2 -CKS2 and Breast Cancer
 3
DMPK 19q13.32 DM, DM1, DMK, MDPK, DM1PK, MT-PK -DMPK and Breast Cancer
 3
DLG1 3q29 hdlg, DLGH1, SAP97, SAP-97, dJ1061C18.1.1 -DLG1 and Breast Cancer
 3
GUSB 7q11.21 BG, MPS7 -GUSB and Breast Cancer
 3
ROCK2 2p24 ROCK-II -ROCK2 and Breast Cancer
 3
GPX2 14q23.3 GPRP, GPx-2, GI-GPx, GPRP-2, GPx-GI, GSHPx-2, GSHPX-GI -GPX2 and Breast Cancer
 3
ITGB2 21q22.3 LAD, CD18, MF17, MFI7, LCAMB, LFA-1, MAC-1 -ITGB2 and Breast Cancer
 3
DLEC1 3p22.2 F56, DLC1, DLC-1, CFAP81 -DLEC1 and Breast Cancer
 3
CBLB 3q13.11 Cbl-b, RNF56, Nbla00127 -CBLB and Breast Cancer
 3
JAG2 14q32.33 HJ2, SER2 -JAG2 and Breast Cancer
 3
ATP7B 13q14.3 WD, PWD, WC1, WND -ATP7B and Breast Cancer
 3
CDK12 17q12 CRK7, CRKR, CRKRS -CDK12 and Breast Cancer
 3
RABEP1 17p13.2 RAB5EP, RABPT5 -RABEP1 and Breast Cancer
 3
MBD1 18q21.1 RFT, PCM1, CXXC3 -MBD1 and Breast Cancer
 3
BTRC 10q24.32 FWD1, FBW1A, FBXW1, bTrCP, FBXW1A, bTrCP1, betaTrCP, BETA-TRCP -BTRC and Breast Cancer
 3
WNT5B 12p13.33 -WNT5B and Breast Cancer
 3
MYCBP 1p34.3 AMY-1 -MYCBP and Breast Cancer
 3
CHAT 10q11.23 CMS6, CMS1A, CMS1A2, CHOACTASE -CHAT and Breast Cancer
 3
HDGF 1q23.1 HMG1L2 -HDGF and Breast Cancer
 3
WNT7A 3p25 -WNT7A and Breast Cancer
 3
LIMK1 7q11.23 LIMK, LIMK-1 -LIMK1 and Breast Cancer
 3
LGALS4 19q13.2 GAL4, L36LBP -LGALS4 and Breast Cancer
 3
NNAT 20q11.23 Peg5 -NNAT and Breast Cancer
 3
NKX2-5 5q35.1 CSX, CSX1, VSD3, CHNG5, HLHS2, NKX2E, NKX2.5, NKX4-1 -NKX2-5 and Breast Cancer
 3
LIPA 10q23.31 LAL, CESD -LIPA and Breast Cancer
 3
SELENOP 5p12 SeP, SELP, SEPP, SEPP1 -SEPP1 and Breast Cancer
 3
CASP2 7q34 ICH1, NEDD2, CASP-2, NEDD-2, PPP1R57 -CASP2 and Breast Cancer
 3
PTPRK 6q22.33 R-PTP-kappa -PTPRK and Breast Cancer
 3
PPP2R1A 19q13.41 MRD36, PP2AA, PR65A, PP2AAALPHA, PP2A-Aalpha -PPP2R1A and Breast Cancer
 3
SLPI 20q13.12 ALP, MPI, ALK1, BLPI, HUSI, WAP4, WFDC4, HUSI-I -SLPI and Breast Cancer
 3
RAD23B 9q31.2 P58, HR23B, HHR23B -RAD23B and Breast Cancer
 3
PRSS1 7q34 TRP1, TRY1, TRY4, TRYP1 -PRSS1 and Breast Cancer
 3
IL21 4q27 Za11, IL-21, CVID11 -IL21 and Breast Cancer
 3
FOLR1 11q13.4 FBP, FOLR -FOLR1 and Breast Cancer
 3
PEG3 19q13.43 PW1, ZNF904, ZSCAN24, ZKSCAN22 -PEG3 and Breast Cancer
 3
SMAD6 15q22.31 AOVD2, MADH6, MADH7, HsT17432 -SMAD6 and Breast Cancer
 3
AQP3 9p13.3 GIL, AQP-3 -AQP3 and Breast Cancer
 3
LRP1B 2q21.2 LRPDIT, LRP-DIT -LRP1B and Breast Cancer
 3
RARRES1 3q25.32 LXNL, TIG1, PERG-1 -RARRES1 and Breast Cancer
 3
PATZ1 22q12.2 ZSG, MAZR, PATZ, RIAZ, ZBTB19, ZNF278, dJ400N23 -PATZ1 and Breast Cancer
 3
GALM 2p22.1 GLAT, IBD1, BLOCK25, HEL-S-63p -GALM and Breast Cancer
 3
PAPPA 9q33.1 PAPA, DIPLA1, PAPP-A, PAPPA1, ASBABP2, IGFBP-4ase -PAPPA and Breast Cancer
 3
MT1G 16q13 MT1, MT1K -MT1G and Breast Cancer
 3
KCNQ1OT1 11p15.5 LIT1, Kncq1, KvDMR1, KCNQ10T1, KCNQ1-AS2, KvLQT1-AS, NCRNA00012 -KCNQ1OT1 and Breast Cancer
 3
MSI1 12q24 -MSI1 and Breast Cancer
 3
MAP3K8 10p11.23 COT, EST, ESTF, TPL2, AURA2, MEKK8, Tpl-2, c-COT -MAP3K8 and Breast Cancer
 3
IL12B 5q33.3 CLMF, NKSF, CLMF2, IMD28, IMD29, NKSF2, IL-12B -IL12B and Breast Cancer
 3
TPM4 19p13.12-p13.11 HEL-S-108 -TPM4 and Breast Cancer
 3
PRKCE 2p21 PKCE, nPKC-epsilon -PRKCE and Breast Cancer
 3
HAS3 16q22.1 -HAS3 and Breast Cancer
 3
TM4SF1 3q25.1 L6, H-L6, M3S1, TAAL6 -TM4SF1 and Breast Cancer
 3
CCN5 20q13.12 CT58, WISP2, CTGF-L -WISP2 and Breast Cancer
 3
MEF2C 5q14.3 DEL5q14.3, C5DELq14.3 -MEF2C and Breast Cancer
 3
RBM5 3p21.31 G15, H37, RMB5, LUCA15 -RBM5 and Breast Cancer
 3
IL2RA 10p15.1 p55, CD25, IL2R, IMD41, TCGFR, IDDM10 -IL2RA and Breast Cancer
 3
ST5 11p15.4 HTS1, p126, DENND2B -ST5 and Breast Cancer
 3
PCM1 8p22 PTC4, RET/PCM-1 -PCM1 and Breast Cancer
 3
ITGB4 17q25.1 CD104, GP150 -ITGB4 and Breast Cancer
 3
USP6 17p13.2 HRP1, TRE2, TRE17, Tre-2, TRESMCR, USP6-short -USP6 and Breast Cancer
 3
LAMP1 13q34 LAMPA, CD107a, LGP120 -LAMP1 and Breast Cancer
 3
HTRA1 10q26.13 L56, HtrA, ARMD7, ORF480, PRSS11, CARASIL, CADASIL2 -HTRA1 and Breast Cancer
 3
GAS7 17p13.1 -GAS7 and Breast Cancer
 2
TSPO 22q13.2 DBI, IBP, MBR, PBR, PBS, BPBS, BZRP, PKBS, PTBR, mDRC, pk18 -TSPO and Breast Cancer
 2
CTNND1 11q12.1 CAS, p120, CTNND, P120CAS, P120CTN, p120(CAS), p120(CTN) -CTNND1 and Breast Cancer
 2
RASSF6 4q13.3 -RASSF6 and Breast Cancer
 2
ABCB5 7p21.1 ABCB5beta, EST422562, ABCB5alpha -ABCB5 and Breast Cancer
 2
ZNF331 19q13.42 RITA, ZNF361, ZNF463 -ZNF331 and Breast Cancer
 2
HSP90AA1 14q32.31 EL52, HSPN, LAP2, HSP86, HSPC1, HSPCA, Hsp89, Hsp90, LAP-2, HSP89A, HSP90A, HSP90N, Hsp103, HSPCAL1, HSPCAL4, HEL-S-65p -HSP90AA1 and Breast Cancer
 2
EXTL1 1p36.11 EXTL -EXTL1 and Breast Cancer
 2
HSD11B1 1q32.2 HDL, 11-DH, HSD11, HSD11B, HSD11L, CORTRD2, SDR26C1, 11-beta-HSD1 -HSD11B1 and Breast Cancer
 2
SLC22A18 11p15.4 HET, ITM, BWR1A, IMPT1, TSSC5, ORCTL2, BWSCR1A, SLC22A1L, p45-BWR1A -SLC22A18 and Breast Cancer
 2
PTPRF 1p34.2 LAR, BNAH2 -PTPRF and Breast Cancer
 2
ARF1 1q42.13 PVNH8 -ARF1 and Breast Cancer
 2
BRD3 9q34.2 ORFX, RING3L -BRD3 and Breast Cancer
 2
TRIM27 6p22.1 RFP, RNF76 -TRIM27 and Breast Cancer
 2
PDGFRL 8p22 PDGRL, PRLTS -PDGFRL and Breast Cancer
 2
AKAP13 15q25.3 BRX, LBC, p47, HA-3, Ht31, c-lbc, PRKA13, AKAP-13, AKAP-Lbc, ARHGEF13, PROTO-LB, PROTO-LBC -AKAP13 and Breast Cancer
 2
PDCD6 5p15.33 ALG2, ALG-2, PEF1B -PDCD6 and Breast Cancer
 2
PRDX6 1q25.1 PRX, p29, AOP2, 1-Cys, NSGPx, aiPLA2, HEL-S-128m -PRDX6 and Breast Cancer
 2
GJA1 6q22.31 HSS, CMDR, CX43, EKVP, GJAL, ODDD, AVSD3, HLHS1 -GJA1 and Breast Cancer
 2
PTPRT 20q12-q13.11 RPTPrho -PTPRT and Breast Cancer
 2
KDM5A 12p13.33 RBP2, RBBP2, RBBP-2 -KDM5A and Breast Cancer
 2
RAP1GDS1 4q23 GDS1, SmgGDS -RAP1GDS1 and Breast Cancer
 2
PERP 6q24 THW, KCP1, PIGPC1, KRTCAP1, dJ496H19.1 -PERP and Breast Cancer
 2
MIR10B 2q31.1 MIRN10B, mir-10b, miRNA10B, hsa-mir-10b -MIR10B and Breast Cancer
 2
ODC1 2p25 ODC -ODC1 and Breast Cancer
 2
TTL 2q13 -TTL and Breast Cancer
 2
ACSL3 2q34-q35 ACS3, FACL3, PRO2194 -ACSL3 and Breast Cancer
 2
MGEA5 10q24.32 OGA, MEA5, NCOAT -MGEA5 and Breast Cancer
 2
MIR106B 7q22.1 MIRN106B, mir-106b -MIR106B and Breast Cancer
 2
ACVRL1 12q13.13 HHT, ALK1, HHT2, ORW2, SKR3, ALK-1, TSR-I, ACVRLK1 -ACVRL1 and Breast Cancer
 2
EPHA1 7q34-q35 EPH, EPHT, EPHT1 -EPHA1 and Breast Cancer
 2
IL1RL1 2q12 T1, ST2, DER4, ST2L, ST2V, FIT-1, IL33R -IL1RL1 and Breast Cancer
 2
FTL 19q13.33 LFTD, NBIA3 -FTL and Breast Cancer
 2
GALT 9p13.3 -GALT and Breast Cancer
 2
GLIPR1 12q21.2 GLIPR, RTVP1, CRISP7 -GLIPR1 and Breast Cancer
 2
C2orf40 2q12.2 ECRG4 -C2orf40 and Breast Cancer
 2
MIR1258 2q31.3 MIRN1258, mir-1258, hsa-mir-1258 -MicroRNA miR-1258 and Breast Cancer
 2
MAX 14q23.3 bHLHd4 -MAX and Breast Cancer
 2
PAWR 12q21 PAR4, Par-4 -PAWR and Breast Cancer
 2
LIMD1 3p21.31 -LIMD1 and Breast Cancer
 2
RNF217-AS1 6q22.31 STL -STL and Breast Cancer
 2
KMT2D 12q13.12 ALR, KMS, MLL2, MLL4, AAD10, KABUK1, TNRC21, CAGL114 -KMT2D and Breast Cancer
 2
CTDSPL 3p22.2 PSR1, SCP3, HYA22, RBSP3, C3orf8 -CTDSPL and Breast Cancer
 2
RXRG 1q23.3 RXRC, NR2B3 -RXRG and Breast Cancer
 2
ERC1 12p13.33 ELKS, Cast2, ERC-1, RAB6IP2 -ERC1 and Breast Cancer
 2
FEZ1 11q24.2 UNC-76 -FEZ1 and Breast Cancer
 2
SOX5 12p12.1 L-SOX5, LAMSHF, L-SOX5B, L-SOX5F -SOX5 and Breast Cancer
 2
ELK4 1q32.1 SAP1 -ELK4 and Breast Cancer
 2
CD200 3q13.2 MRC, MOX1, MOX2, OX-2 -CD200 and Breast Cancer
 2
PNN 14q21.1 DRS, DRSP, SDK3, memA -PNN and Breast Cancer
 1
CBLC 19q13.32 CBL-3, RNF57, CBL-SL -CBLC and Breast Cancer
 1
PRTN3 19p13.3 MBN, MBT, NP4, P29, PR3, ACPA, AGP7, NP-4, PR-3, CANCA, C-ANCA -PRTN3 and Breast Cancer
 1
KAT6B 10q22.2 qkf, MORF, MOZ2, GTPTS, MYST4, ZC2HC6B, querkopf -KAT6B and Breast Cancer
 1
SERPINB2 18q21.33-q22.1 PAI, PAI2, PAI-2, PLANH2, HsT1201 -SERPINB2 and Breast Cancer
 1
IL17A 6p12.2 IL17, CTLA8, IL-17, CTLA-8, IL-17A -IL17A and Breast Cancer
 1
CRTC3 15q26.1 TORC3, TORC-3 -CRTC3 and Breast Cancer
 1
PECAM1 17q23.3 CD31, PECA1, GPIIA', PECAM-1, endoCAM, CD31/EndoCAM -PECAM1 and Breast Cancer
 1
CNTRL 9q33.2 FAN, CEP1, CEP110, bA165P4.1 -CNTRL and Breast Cancer
 1
PPP2CB 8p12 PP2CB, PP2Abeta -PPP2CB and Breast Cancer
 1
ITGAX 16p11.2 CD11C, SLEB6 -ITGAX and Breast Cancer
 1
GPRC6A 6q22.1 GPCR, bA86F4.3 -GPRC6A and Breast Cancer
 1
COX6C 8q22.2 -COX6C and Breast Cancer
 1
RAB8A 19p13.11 MEL, RAB8 -RAB8A and Breast Cancer
 1
SRGAP3 3p25.3 WRP, MEGAP, SRGAP2, ARHGAP14 -SRGAP3 and Breast Cancer
 1
PLCD1 3p22.2 NDNC3, PLC-III -PLCD1 and Breast Cancer
 1
EIF4A2 3q27.3 DDX2B, EIF4A, EIF4F, BM-010, eIF4A-II, eIF-4A-II -EIF4A2 and Breast Cancer
 1
OMD 9q22.31 OSAD, SLRR2C -OMD and Breast Cancer
 1
S100A3 1q21.3 S100E -S100A3 and Breast Cancer
 1
PPP2CA 5q31.1 RP-C, PP2Ac, PP2CA, PP2Calpha -PPP2CA and Breast Cancer
 1
TRG 7p14.1 TCRG, TRG@ -TRG and Breast Cancer
 1
SEPTIN5 22q11.21 H5, SEPT5, CDCREL, PNUTL1, CDCREL1, CDCREL-1, HCDCREL-1 -SEPT5 and Breast Cancer
 1
ETV3 1q23.1 PE1, METS, PE-1 -ETV3 and Breast Cancer
 1
ARHGEF12 11q23.3 LARG, PRO2792 -ARHGEF12 and Breast Cancer
 1
SUPT5H 19q13.2 SPT5, SPT5H, Tat-CT1 -SUPT5H and Breast Cancer
 1
ARHGEF5 7q35 P60, TIM, GEF5, TIM1 -ARHGEF5 and Breast Cancer
 1
ANXA8 10q11.22 ANX8, CH17-360D5.2 -ANXA8 and Breast Cancer
FLCN 17p11.2 BHD, FLCL -FLCN and Breast Cancer
PTPRH 19q13.42 SAP1, R-PTP-H -PTPRH and Breast Cancer
ANXA5 4q27 PP4, ANX5, ENX2, RPRGL3, HEL-S-7 -ANXA5 and Breast Cancer
HOXC10 12q13.3 HOX3I Epigenetics
 -HOXC10 Silencing in ER positive Breast Cancer
TUBE1 6q21 TUBE, dJ142L7.2 -TUBE1 and Breast Cancer
SERPINC1 1q25.1 AT3, AT3D, ATIII, THPH7, ATIII-R2, ATIII-T1, ATIII-T2 -SERPINC1 and Breast Cancer
AVPR1B 1q32.1 V1bR, AVPR3 -AVPR1B and Breast Cancer
FLNC 7q32.1 ABPA, ABPL, FLN2, MFM5, MPD4, RCM5, CMH26, ABP-280, ABP280A -FLNC and Breast Cancer
FSTL3 19p13.3 FLRG, FSRP -FSTL3 and Breast Cancer

Note: list is not exhaustive. Number of papers are based on searches of PubMed (click on topic title for arbitrary criteria used).

Latest Publications

Hadj-Ahmed M, Ghali RM, Bouaziz H, et al.
Transforming growth factor beta 1 polymorphisms and haplotypes associated with breast cancer susceptibility: A case-control study in Tunisian women.
Tumour Biol. 2019; 41(8):1010428319869096 [PubMed] Related Publications
Variable association of transforming growth factor beta 1 (TGFβ1) in breast cancer (BC) pathogenesis was documented, and the contribution of specific
Related: TGFB1

Yue CH, Liu JY, Chi CS, et al.
Myeloid Zinc Finger 1 (MZF1) Maintains the Mesenchymal Phenotype by Down-regulating IGF1R/p38 MAPK/ERα Signaling Pathway in High-level MZF1-expressing TNBC cells.
Anticancer Res. 2019; 39(8):4149-4164 [PubMed] Related Publications
BACKGROUND/AIM: Signaling regulation of myeloid zinc finger 1 (MZF1) has been implicated in the progression of many human malignancies; however, the mechanistic action of MZF1 in triple-negative breast cancer (TNBC) progression remains elusive. In this study, the aim was to investigate the molecular mechanisms of MZF1 and its functional role in TNBC cellular migration and invasion.
MATERIALS AND METHODS: Hs578T and MDA-MB-231 cells were transfected to stably express the acidic domain of MZF1 (MZF1
RESULTS: Herein, we found that MZF1 in high-level MZF1-expressing TNBC cells is associated with cell migration, invasion, and mesenchymal phenotype. MZF1 interacted with the promoter region of insulin-like growth factor 1 receptor (IGF1R) to drive invasion and metastasis of high-level MZF1-expressing TNBC cells. Exogenous expression of the acidic domain of MZF1 repressed the binding of endogenous MZF1 to IGF1R promoter via blocking the interaction with ETS-like gene 1 (ELK1). This blockage not only caused MZF1 protein degradation, but also restrained ELK1 nuclear localization in high-level MZF1-expressing TNBC cells. MZF1, but not ELK1, was necessary for the retention of mesenchymal phenotype by repressing IGF1R promoter activity in TNBC cells expressing high levels of MZF1. Activation of the IGF1R-driven p38MAPK-ERα-slug-E-cadherin signaling axis mediated the conversion of mesenchymal cell to epithelial phenotype, caused by MZF1 destabilization. These results suggest that MZF1 is an oncogenic inducer.
CONCLUSION: Blocking of the MZF1/ELK1 interaction to reduce MZF1 protein stability by saturating the endogenous MZF1/ELK1 binding domains might be a promising therapeutic strategy for the treatment of high-level MZF1-expressing TNBC.
Related: Signal Transduction ELK1 ESR1

Chen Y, Liu L, Ni R, Zhou W
Advances in HER2 testing.
Adv Clin Chem. 2019; 91:123-162 [PubMed] Related Publications
HER2-positive breast cancer is a particularly aggressive type of breast cancer. Indication of HER2 positivity is essential for its treatment. In addition to a few FDA-approved methods such as immunohistochemical (IHC) detection of HER2 protein expression and in situ hybridization (ISH) assessment of HER2 gene amplification, several novel methods have been developed for HER2 testing in recent years. This chapter provides an overview of HER2 testing with emphasis on those new methods.

Tokgun PE, Tokgun O, Kurt S, et al.
MYC-driven regulation of long non-coding RNA profiles in breast cancer cells.
Gene. 2019; 714:143955 [PubMed] Related Publications
AIM: MYC deregulation contributes to breast cancer development and progression. Deregulated expression levels of long non-coding RNAs (lncRNA) have been demonstrated to be critical players in development and/or maintenance of breast cancer. In this study we aimed to evaluate lncRNA expressions depending on MYC overexpression and knockdown in breast cancer cells.
MATERIALS AND METHODS: Cells were infected with lentiviral vectors by either knockdown or overexpression of c-MYC. LncRNA cDNA was transcribed from total RNA samples and lncRNAs were evaluated by qRT-PCR.
RESULTS: Our results indicated that some of the lncRNAs having tumor suppressor (GAS5, MEG3, lincRNA-p21) and oncogenic roles (HOTAIR) are regulated by c-MYC.
CONCLUSION: We observed that c-MYC regulates lncRNAs that have important roles on proliferation, cell cycle and etc. Further studies will give us a light to identify molecular mechanisms related to MYC-lncRNA regulatory pathways in breast cancer.
Related: MYC

Yu QC, Song B, Zou XX, et al.
[Analysis of normal tissues adjacent to the tumour-specific expressed genes in breast cancer].
Yi Chuan. 2019; 41(7):625-633 [PubMed] Related Publications
Normal tissues adjacent to the tumour (NAT) are widely used as controls in comparative studies to search for cancer-associated genes. However, the gene expression profiles between NAT and non-tumour-bearing tissues are different. The presence of NAT-specific expressed genes often hinders traditional transcriptional profiles studies. Further, studies on the differences in gene expression profiles between NAT and tumour-free tissues are infrequently performed. In this study, we sequenced and analysed the transcriptomes of tumour tissues (T), matched NAT and contralateral breast normal tissues (CBN) of 14 breast cancer patients, and identified 102 differentially expressed genes (DEGs) between CBN and NAT. Gene enrichment and protein-protein interaction (PPI) analyses revealed that these DEGs are significantly enriched in TNF (tumour necrosis factor) signalling and EMT (epithelial-mesenchymal transition) gene sets closely associated with oncogenesis. Comparative analyses of the transcriptomic profiles between NAT and CBN, NAT and T identified 23 NAT-specific highly-expressed genes, namely tumour-adjacent speci?cally activated (TASA) genes. These genes were significantly enriched in TNF signalling gene set, and 15 of which have not been previously reported. The results indicate that TASA genes are common in adjacent tissues and are related to the TNF signalling in the immune system. The tumour-adjacent tissues harbour tumour-like expressed genes that could contribute to tumour initiation but are often missed in NAT-T pair-wise studies.
Related: Signal Transduction TNF

Ramezani S, Sharafshah A, Mirzanejad L, Hadavi M
Association of PARP1 rs4653734, rs907187 and rs1136410 variants with breast cancer risk among Iranian women.
Gene. 2019; 712:143954 [PubMed] Related Publications
BACKGROUND: Breast cancer (BC) is the highest cause of mortality among female cancer patients. In some cases, BC is due to Poly [ADP-ribose] polymerase 1 (PARP1) gene dysregulation, which has been involved in various important cellular processes. Among Iranian women, the association between PARP1 polymorphisms and BC was never studied before so in this case-control study, the genetic association of three SNPs (rs1136410, rs907187 and rs4653734) was analyzed with susceptibility to BC.
METHODS: The study subjects were 386 Iranian females divided into 186 patients and 200 healthy controls. The genotypes of PARP1 variants were detected using ARMS and a combined ARMS-RFLP PCR method.
RESULTS: The results showed that Carriers of CG and GG genotypes of the variant rs4653734 were at higher risk of BC compared with wild-type carriers (CC) and this variant was statistically significant under a recessive model of inheritance. Moreover, rs907187 was related to increased BC risk in the CC and GG genotypes under dominant and recessive models of inheritance. The G allele frequency of rs4653734 and rs907187 was higher in breast cancer patients than in normal subjects. No association was detected between rs1136410 and susceptibility to BC among studied groups. Furthermore, A-G-C haplotype was linked to an increased BC risk, whereas A-C-C and A-C-G haplotypes were related to a decreased risk of BC. In Silico predictions suggested that rs907187 affects E2F and E2F-4 transcription factors binding site.
CONCLUSIONS: The current study suggests that rs907187 and rs4653734 have remarkable associations with BC risk among Iranian women.
Related: PARP1

Zhou Q, Ren J, Hou J, et al.
Co-expression network analysis identified candidate biomarkers in association with progression and prognosis of breast cancer.
J Cancer Res Clin Oncol. 2019; 145(9):2383-2396 [PubMed] Related Publications
PURPOSE: Breast cancer is one of the most common malignancies among females, and its prognosis is affected by a complex network of gene interactions. Weighted gene co-expression network analysis was used to construct free-scale gene co-expression networks and to identify potential biomarkers for breast cancer progression.
METHODS: The gene expression profiles of GSE42568 were downloaded from the Gene Expression Omnibus database. RNA-sequencing data and clinical information of breast cancer from TCGA were used for validation.
RESULTS: A total of ten modules were established by the average linkage hierarchical clustering. We identified 58 network hub genes in the significant module (R
CONCLUSIONS: AGO2, CDC20, CDCA5, MCM10, MYBL2, and TTK were identified as candidate biomarkers for further basic and clinical research on breast cancer based on co-expression analysis.

Lopes MB, Casimiro S, Vinga S
Twiner: correlation-based regularization for identifying common cancer gene signatures.
BMC Bioinformatics. 2019; 20(1):356 [PubMed] Free Access to Full Article Related Publications
BACKGROUND: Breast and prostate cancers are typical examples of hormone-dependent cancers, showing remarkable similarities at the hormone-related signaling pathways level, and exhibiting a high tropism to bone. While the identification of genes playing a specific role in each cancer type brings invaluable insights for gene therapy research by targeting disease-specific cell functions not accounted so far, identifying a common gene signature to breast and prostate cancers could unravel new targets to tackle shared hormone-dependent disease features, like bone relapse. This would potentially allow the development of new targeted therapies directed to genes regulating both cancer types, with a consequent positive impact in cancer management and health economics.
RESULTS: We address the challenge of extracting gene signatures from transcriptomic data of prostate adenocarcinoma (PRAD) and breast invasive carcinoma (BRCA) samples, particularly estrogen positive (ER+), and androgen positive (AR+) triple-negative breast cancer (TNBC), using sparse logistic regression. The introduction of gene network information based on the distances between BRCA and PRAD correlation matrices is investigated, through the proposed twin networks recovery (twiner) penalty, as a strategy to ensure similarly correlated gene features in two diseases to be less penalized during the feature selection procedure.
CONCLUSIONS: Our analysis led to the identification of genes that show a similar correlation pattern in BRCA and PRAD transcriptomic data, and are selected as key players in the classification of breast and prostate samples into ER+ BRCA/AR+ TNBC/PRAD tumor and normal tissues, and also associated with survival time distributions. The results obtained are supported by the literature and are expected to unveil the similarities between the diseases, disclose common disease biomarkers, and help in the definition of new strategies for more effective therapies.
Related: Prostate Cancer

Huang YB, Song FJ, Chen KX
[Application values of genome-wide association studies in screening for breast cancer].
Zhonghua Liu Xing Bing Xue Za Zhi. 2019; 40(6):713-718 [PubMed] Related Publications
Related: Cancer Screening and Early Detection

Guo JQ, Wang S, Zhou WJ, et al.
[Correlation between single nucleotide polymorphisms of rs4778137 located in OCA2 gene and clinical response of breast cancer patients receiving neoadjuvant chemotherapy].
Zhonghua Yi Xue Za Zhi. 2019; 99(22):1712-1716 [PubMed] Related Publications

Sachdev JC, Sandoval AC, Jahanzeb M
Update on Precision Medicine in Breast Cancer.
Cancer Treat Res. 2019; 178:45-80 [PubMed] Related Publications
Precision medicine approaches have found applications in the treatment of several tumor types and have led to rapid advancement in the number of available therapies for some difficult-to-treat diseases. In comparison to tumors like EGFR-mutated lung cancer, and BRAF-mutated melanoma for example, precision medicine in breast cancer is still in its infancy despite the much earlier identification of targets like ER and HER2. Though significant progress has been made in new therapies for hormone-receptor-positive and HER2-positive breast cancers, identification of molecular heterogeneity and lack of other valid reproducible targets in triple-negative breast cancer remain a challenge. In this chapter, we outline the recent advances in technology and targeted treatments for breast cancer, the remaining challenges and ongoing efforts to address these to make precision medicine a reality for all breast cancer patients.
Related: Lung Cancer Risk Factors and Prevention of Lung Cancer

Bao Y, Wang L, Shi L, et al.
Transcriptome profiling revealed multiple genes and ECM-receptor interaction pathways that may be associated with breast cancer.
Cell Mol Biol Lett. 2019; 24:38 [PubMed] Free Access to Full Article Related Publications
Background: Exploration of the genes with abnormal expression during the development of breast cancer is essential to provide a deeper understanding of the mechanisms involved. Transcriptome sequencing and bioinformatics analysis of invasive ductal carcinoma and paracancerous tissues from the same patient were performed to identify the key genes and signaling pathways related to breast cancer development.
Methods: Samples of breast tumor tissue and paracancerous breast tissue were obtained from 6 patients. Sequencing used the Illumina HiSeq platform. All. Only perfectly matched clean reads were mapped to the reference genome database, further analyzed and annotated based on the reference genome information. Differentially expressed genes (DEGs) were identified using the DESeq R package (1.10.1) and DEGSeq R package (1.12.0). Using KOBAS software to execute the KEGG bioinformatics analyses, enriched signaling pathways of DEGs involved in the occurrence of breast cancer were determined. Subsequently, quantitative real time PCR was used to verify the accuracy of the expression profile of key DEGs from the RNA-seq result and to explore the expression patterns of novel cancer-related genes on 8 different clinical individuals.
Results: The transcriptomic sequencing results showed 937 DEGs, including 487 upregulated and 450 downregulated genes in the breast cancer specimens. Further quantitative gene expression analysis was performed and captured 252 DEGs (201 downregulated and 51 upregulated) that showed the same differential expression pattern in all libraries. Finally, 6 upregulated DEGs (CST2, DRP2, CLEC5A, SCD, KIAA1211, DTL) and 6 downregulated DEGs (STAC2, BTNL9, CA4, CD300LG, GPIHBP1 and PIGR), were confirmed in a quantitative real time PCR comparison of breast cancer and paracancerous breast tissues from 8 clinical specimens. KEGG analysis revealed various pathway changes, including 20 upregulated and 21 downregulated gene enrichment pathways. The extracellular matrix-receptor (ECM-receptor) interaction pathway was the most enriched pathway: all genes in this pathway were DEGs, including the THBS family, collagen and fibronectin. These DEGs and the ECM-receptor interaction pathway may perform important roles in breast cancer.
Conclusion: Several potential breast cancer-related genes and pathways were captured, including 7 novel upregulated genes and 76 novel downregulated genes that were not found in other studies. These genes are related to cell proliferation, movement and adhesion. They may be important for research into breast cancer mechanisms, particularly CST2 and CA4. A key signaling pathway, the ECM-receptor interaction signal pathway, was also identified as possibly involved in the development of breast cancer.
Related: Signal Transduction

Feng T, Zhang P, Sun Y, et al.
High throughput sequencing identifies breast cancer-secreted exosomal LncRNAs initiating pulmonary pre-metastatic niche formation.
Gene. 2019; 710:258-264 [PubMed] Related Publications
OBJECTIVE: Increasing evidence indicated that cancer-secreted exosomes played an important role in tumor metastasis. However, the function of exosomes in breast cancer pulmonary metastasis remains unknown. The aim of the study was to investigate the role of exosome-derived from breast cancer-secreted long non-coding RNAs (LncRNAs) on pre-metastatic niche formation in pulmonary metastasis.
METHODS: Exosomes-derived from breast cancer were separated by ultracentrifugation. The high-throughput sequencing, Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway were used to detect and evaluate the differential expression of LncRNAs in lung fibroblasts with exosomes treated. And quantitative real-time polymerase chain reaction (qRT-PCR) was performed to verify candidate LncRNAs expression.
RESULTS: We found that exosomes-derived from breast cancer induced lung fibroblasts proliferation and migration. In addition, a large number of LncRNAs expression abnormalities were involved in the breast cancer lung metastasis microenvironment.
CONCLUSION: Our findings suggested that exosomal LncRNAs facilitated tumor pre-metastatic niche formation and represented a novel mechanistic insight into the molecular mechanism of cancer metastasis microenvironment.

Masoodi TA, Shaik NA, Burhan S, et al.
Structural prediction, whole exome sequencing and molecular dynamics simulation confirms p.G118D somatic mutation of PIK3CA as functionally important in breast cancer patients.
Comput Biol Chem. 2019; 80:472-479 [PubMed] Related Publications
To understand the structural and functional importance of PIK3CA somatic mutations, whole exome sequencing, molecular dynamics simulation techniques in combination with in silico prediction algorithms such as SIFT, PolyPhen, Provean and CADD were employed. Twenty out of eighty missense somatic mutations in PIK3CA gene were found to be pathogenic by all the four algorithms. Most recurrent mutations found were known hotspot PIK3CA mutations with known clinical significance like p.E545 K, p.E545A, p.E545 G and p.C420R. A missense mutation p.G118D was found to be recurrently mutated in 5 cases. Interestingly, this mutation was observed in one of the patients who underwent whole exome sequencing and was completely absent from the controls. To see the effect of this mutation on the structure of PIK3CA protein, molecular dynamics simulation was performed. By molecular dynamics approach, we have shown that p.G118D mutation deviated from the native structure which was supported by the decrease in the number of hydrogen bonds, difference in hydrogen bond distance and angle, difference in root mean square deviation between the native and the mutant structures.

Nam KJ, Park H, Ko ES, et al.
Radiomics signature on 3T dynamic contrast-enhanced magnetic resonance imaging for estrogen receptor-positive invasive breast cancers: Preliminary results for correlation with Oncotype DX recurrence scores.
Medicine (Baltimore). 2019; 98(23):e15871 [PubMed] Free Access to Full Article Related Publications
To evaluate the ability of a radiomics signature based on 3T dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) to distinguish between low and non-low Oncotype DX (OD) risk groups in estrogen receptor (ER)-positive invasive breast cancers.Between May 2011 and March 2016, 67 women with ER-positive invasive breast cancer who performed preoperative 3T MRI and OD assay were included. We divided the patients into low (OD recurrence score [RS] <18) and non-low risk (RS ≥18) groups. Extracted radiomics features included 8 morphological, 76 histogram-based, and 72 higher-order texture features. A radiomics signature (Rad-score) was generated using the least absolute shrinkage and selection operator (LASSO). Univariate and multivariate logistic regression analyses were performed to investigate the association between clinicopathologic factors, MRI findings, and the Rad-score with OD risk groups, and the areas under the receiver operating characteristic curves (AUC) were used to assess classification performance of the Rad-score.The Rad-score was constructed for each tumor by extracting 10 (6.3%) from 158 radiomics features. A higher Rad-score (odds ratio [OR], 65.209; P <.001), Ki-67 expression (OR, 17.462; P = .007), and high p53 (OR = 8.449; P = .077) were associated with non-low OD risk. The Rad-score classified low and non-low OD risk with an AUC of 0.759.The Rad-score showed the potential for discrimination between low and non-low OD risk groups in patients with ER-positive invasive breast cancers.

Tao L, Wu YQ, Zhang SP
MiR-21-5p enhances the progression and paclitaxel resistance in drug-resistant breast cancer cell lines by targeting PDCD4.
Neoplasma. 2019; 2019 [PubMed] Related Publications
MiR-21-5p has been identified as an oncogene to enhance human tumor progression. Here, we explored the mechanism by which miR-21-5p regulated the progression and paclitaxel (PTX) resistance in drug-resistant breast cancer (BC) cell lines. qRT-PCR assays were used to assess the expression levels of miR-21-5p and PDCD4 mRNA, and western blotting was used to detect PDCD4 protein level in PTX-resistant BC cell lines. Dual-luciferase reporter assay was used to observe the interaction between miR-21-5p and PDCD4 in PTX-resistant BC cell lines. Cell proliferation ability and IC50 values of PTX were measured by CCK-8 assay, cell cycle progression and apoptosis were determined with flow cytometry analysis, and cell migration and invasion capacities were analyzed using Transwell assay. Xenograft mice assay was used to validate the important role of miR-21-5p as a regulator on PTX-resistance BC cells growth in vivo. Then, we found that miR-21-5p was upregulated and PDCD4 was downregulated in BC tissues and PTX-resistant BC cell lines. MiR-21-5p silencing or PDCD4 overexpression ameliorated PTX resistance and inhibited the progression in PTX-resistant BC cell lines. Moreover, PDCD4 was demonstrated to be a direct target of miR-21-5p. MiR-21-5p exerted its regulatory effect by PDCD4 in PTX-resistant BC cell lines. Additionally, miR-21-5p silencing inhibited tumor growth in vivo. Therefore, our study demonstrated that miR-21-5p silencing ameliorated PTX resistance and inhibited the progression in PTX-resistant BC cell lines at least partly by targeting PDCD4, providing miR-21-5p as an effective therapeutic target for PTX-resistant BC treatment.
Related: Apoptosis MicroRNAs Paclitaxel microRNA mir-21 PDCD4

Zhu Y, Zou X, Dean AE, et al.
Lysine 68 acetylation directs MnSOD as a tetrameric detoxification complex versus a monomeric tumor promoter.
Nat Commun. 2019; 10(1):2399 [PubMed] Free Access to Full Article Related Publications
Manganese superoxide dismutase (MnSOD) functions as a tumor suppressor; however, once tumorigenesis occurs, clinical data suggest MnSOD levels correlate with more aggressive human tumors, implying a potential dual function of MnSOD in the regulation of metabolism. Here we show, using in vitro transformation and xenograft growth assays that the MnSOD-K68 acetylation (Ac) mimic mutant (MnSOD

Sparano JA, Gray RJ, Ravdin PM, et al.
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.
N Engl J Med. 2019; 380(25):2395-2405 [PubMed] Article available free on PMC after 20/12/2019 Related Publications
BACKGROUND: The use of adjuvant chemotherapy in patients with breast cancer may be guided by clinicopathological factors and a score based on a 21-gene assay to determine the risk of recurrence. Whether the level of clinical risk of breast cancer recurrence adds prognostic information to the recurrence score is not known.
METHODS: We performed a prospective trial involving 9427 women with hormone-receptor-positive, human epidermal growth factor receptor 2-negative, axillary node-negative breast cancer, in whom an assay of 21 genes had been performed, and we classified the clinical risk of recurrence of breast cancer as low or high on the basis of the tumor size and histologic grade. The effect of clinical risk was evaluated by calculating hazard ratios for distant recurrence with the use of Cox proportional-hazards models. The initial endocrine therapy was tamoxifen alone in the majority of the premenopausal women who were 50 years of age or younger.
RESULTS: The level of clinical risk was prognostic of distant recurrence in women with an intermediate 21-gene recurrence score of 11 to 25 (on a scale of 0 to 100, with higher scores indicating a worse prognosis or a greater potential benefit from chemotherapy) who were randomly assigned to endocrine therapy (hazard ratio for the comparison of high vs. low clinical risk, 2.73; 95% confidence interval [CI], 1.93 to 3.87) or to chemotherapy plus endocrine (chemoendocrine) therapy (hazard ratio, 2.41; 95% CI, 1.66 to 3.48) and in women with a high recurrence score (a score of 26 to 100), all of whom were assigned to chemoendocrine therapy (hazard ratio, 3.17; 95% CI, 1.94 to 5.19). Among women who were 50 years of age or younger who had received endocrine therapy alone, the estimated (±SE) rate of distant recurrence at 9 years was less than 5% (≤1.8±0.9%) with a low recurrence score (a score of 0 to 10), irrespective of clinical risk, and 4.7±1.0% with an intermediate recurrence score and low clinical risk. In this age group, the estimated distant recurrence at 9 years exceeded 10% among women with a high clinical risk and an intermediate recurrence score who received endocrine therapy alone (12.3±2.4%) and among those with a high recurrence score who received chemoendocrine therapy (15.2±3.3%).
CONCLUSIONS: Clinical-risk stratification provided prognostic information that, when added to the 21-gene recurrence score, could be used to identify premenopausal women who could benefit from more effective therapy. (Funded by the National Cancer Institute and others; ClinicalTrials.gov number, NCT00310180.).

Budny A, Starosławska E, Budny B, et al.
[Epidemiology and diagnosis of breast cancer].
Pol Merkur Lekarski. 2019; 46(275):195-204 [PubMed] Related Publications
Breast cancer is the most common cancer in women. Family history of breast cancer, age at menarche, number of pregnancies and births, history of breast biopsies, use of hormone replacement therapy and time from the last menstrual period are the key events to note. In addition, a high percentage of cases has been demonstrated in women with a genetically conditioned cancer, i.e. mutations in genes BRCA1, BRCA2, syndromes of Li-Fraumeni, Cowden and Peutz-Jeghers. Over 90% of cases are local or regional when detected. The diagnostics approach consists of self-control, breast palpation by the doctor, breast imaging usually with ultrasound, mammography and magnetic resonance. To confirm the diagnosis, a fine-, core-needle or mammotome biopsy is performed. The final diagnosis is based on a wide panel of immunohistochemical and cytogenetic tests. Histological examination provides accurate assessment of the tumor type, grade, estrogen and progesterone hormone receptor status, HER2 overexpression and Ki67 proliferation index. The data makes possible to qualify to one of four groups of breast cancer biological subtypes, which allows individualized treatment of the patient.

Grosselin K, Durand A, Marsolier J, et al.
High-throughput single-cell ChIP-seq identifies heterogeneity of chromatin states in breast cancer.
Nat Genet. 2019; 51(6):1060-1066 [PubMed] Related Publications
Modulation of chromatin structure via histone modification is a major epigenetic mechanism and regulator of gene expression. However, the contribution of chromatin features to tumor heterogeneity and evolution remains unknown. Here we describe a high-throughput droplet microfluidics platform to profile chromatin landscapes of thousands of cells at single-cell resolution. Using patient-derived xenograft models of acquired resistance to chemotherapy and targeted therapy in breast cancer, we found that a subset of cells within untreated drug-sensitive tumors share a common chromatin signature with resistant cells, undetectable using bulk approaches. These cells, and cells from the resistant tumors, have lost chromatin marks-H3K27me3, which is associated with stable transcriptional repression-for genes known to promote resistance to treatment. This single-cell chromatin immunoprecipitation followed by sequencing approach paves the way to study the role of chromatin heterogeneity, not just in cancer but in other diseases and healthy systems, notably during cellular differentiation and development.

Mu X, Chen M, Xiao B, et al.
EZH2 Confers Sensitivity of Breast Cancer Cells to Taxol by Attenuating p21 Expression Epigenetically.
DNA Cell Biol. 2019; 38(7):651-659 [PubMed] Related Publications
Breast cancer is the leading cause of death in women. Although numerous clinical regimens are used to treat breast cancer and manifest satisfied efficacy, drug resistance is emerging as the major obstacle to their long-term use. It is critically necessary to decipher the molecular mechanism underlying this process to obtain improved and long-term use of each regimen. In the present study, we showed the negative relationship between EZH2 and chemoresistance to taxol in breast cancer cells. EZH2 interference was capable of decreasing while overexpression increasing apoptosis of breast cancer cells challenged with taxol. Meanwhile, p21, the inhibitor of cell cycle entry, interference upregulated, while overexpression downregulated apoptosis induced by taxol. Mechanistically, EZH2 was recruited to the promoter of p21 accompanied with H3K27me3 enrichment and transcription silencing. Collectively, EZH2 attenuates chemoresistance of breast cancer cells to taxol by dampening p21 epigenetically.
Related: Apoptosis CDKN1A Paclitaxel EZH2

Pietilä M, Sahgal P, Peuhu E, et al.
SORLA regulates endosomal trafficking and oncogenic fitness of HER2.
Nat Commun. 2019; 10(1):2340 [PubMed] Article available free on PMC after 20/12/2019 Related Publications
The human epidermal growth factor receptor 2 (HER2) is an oncogene targeted by several kinase inhibitors and therapeutic antibodies. While the endosomal trafficking of many other receptor tyrosine kinases is known to regulate their oncogenic signalling, the prevailing view on HER2 is that this receptor is predominantly retained on the cell surface. Here, we find that sortilin-related receptor 1 (SORLA; SORL1) co-precipitates with HER2 in cancer cells and regulates HER2 subcellular distribution by promoting recycling of the endosomal receptor back to the plasma membrane. SORLA protein levels in cancer cell lines and bladder cancers correlates with HER2 levels. Depletion of SORLA triggers HER2 targeting to late endosomal/lysosomal compartments and impairs HER2-driven signalling and in vivo tumour growth. SORLA silencing also disrupts normal lysosome function and sensitizes anti-HER2 therapy sensitive and resistant cancer cells to lysosome-targeting cationic amphiphilic drugs. These findings reveal potentially important SORLA-dependent endosomal trafficking-linked vulnerabilities in HER2-driven cancers.
Related: Transitional Cell Cancer of the Renal Pelvis and Ureter Bladder Cancer Bladder Cancer - Molecular Biology

Li LH, Xiao B, Muhetaer A, Sun ZH
[Differences in circRNA expression profiles between HER-2-positive breast cancer cells and normal mammary epithelial cells].
Zhonghua Zhong Liu Za Zhi. 2019; 41(5):331-337 [PubMed] Related Publications
Related: MicroRNAs

Galaziou A, Christopoulos TK, Ioannou PC
Paper-based device providing visual genetic signatures for precision medicine: application to breast cancer.
Anal Bioanal Chem. 2019; 411(17):3769-3776 [PubMed] Related Publications
Genome-wide association studies have demonstrated that combinations of single nucleotide polymorphisms (SNPs), rather than individual SNPs, represent genetic signatures that correlate with heterogeneous and complex diseases. In this context, we developed a paper-based device that provides visual detection of a 10-SNP panel as a genetic signature associated with the risk for breast cancer. The method involves multiplex PCR amplification, multiplex extension reaction of allele-specific primers, without prior purification of the amplified sequences, and, finally, capture and visualization of the extension products within minutes on the device. Detection and monitoring are accomplished either by naked eye or by scanning with a common flatbed scanner. The total assay time is ∼ 2 h. The method was evaluated by using 21 clinical samples of known genotypes. The results were fully concordant with the reference method (sequencing). The proposed method is accurate, simple, rapid, and cost-effective. Visual detection does not require specialized instrumentation or highly trained technical personnel. We anticipate that the proposed device will become a useful analytical tool for precision medicine of breast cancer.

Vogel C, Malter W, Morgenstern B, et al.
The Role of Previous Therapies and Sites of Metastasis as Influencing Factors on Discordance of ER, PR and HER2 Status Between Primary and Metastasized Breast Cancer.
Anticancer Res. 2019; 39(5):2647-2659 [PubMed] Related Publications
BACKGROUND/AIM: The aim of the present study was to analyze metastasized breast cancer (BC) patients with regard to the discordance of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2). We especially aimed to analyze the association between the change of tumor biology and previous treatment or metastatic sites.
PATIENTS AND METHODS: Patients with metastasized BC who were treated at the Department of Gynecology/Breast Center of the University Hospital of Cologne were analyzed.
RESULTS: Loss of HER2 occurred more frequently in lymph node metastases that were not in the axillary region (p=0.026). Letrozole showed a significant correlation with loss of ER and/or PR (p=0.041). Improved overall survival and post-metastasis survival were noticed with a gain of HER2 (p=0.044 and p=0.009, respectively) and concordant positive ER and PR status (p=0.002 and p=0.001, respectively).
CONCLUSION: The discordance of receptors and the dependence of BC on therapies as well as metastatic sites stresses the necessity of early sample taking to offer patients suitable therapy options.

Rusak A, Jablonska K, Piotrowska A, et al.
Correlation of Expression of CHI3L1 and Nogo-A and their Role in Angiogenesis in Invasive Ductal Breast Carcinoma.
Anticancer Res. 2019; 39(5):2341-2350 [PubMed] Related Publications
BACKGROUND/AIM: Chitinase 3 like 1 (CHI3L1) is a secretion glycoprotein. Elevated levels of this protein are observed in cancer diseases. The biological role of CHI3L1 is not yet fully known, but the connection between CHI3L1 and angiogenesis has been shown. Recent reports also describe the association of Nogo isoforms and Nogo-B receptor (NgBR) with a proliferative potential, cancer cell invasiveness, and angiogenesis. The aim of this study was to evaluate the levels of CHI3L1, Nogo-A, Nogo-A/B, and NgBR and correlate them with clinical-pathological data, to study their role in angiogenesis in invasive ductal breast carcinoma (IDC).
MATERIALS AND METHODS: A total of 77 IDC cases were used in the study. Immunohistochemistry was used to determine the level of expression of CHI3L1, Nogo-A, Nogo-A/B, NgBR and vascular endothelial growth factors (VEGFA, VEGFC and VEGFD). The obtained results were subjected to statistical analysis including clinicalpathological data.
RESULTS: A statistically significant positive correlation of CHI3L1 and Nogo-A expression (r=0.474, p>0.0001) and a positive correlation of Nogo-A and VEGFC expression (r=0.280, p=0.013) were found.
CONCLUSION: CHI3L1 and Nogo-A are important in angiogenesis in IDC.
Related: Angiogenesis and Cancer VEGFA VEGFC

Tanaka Y, Kosaka Y, Waraya M, et al.
Differential Prognostic Relevance of Promoter DNA Methylation of
Anticancer Res. 2019; 39(5):2289-2298 [PubMed] Related Publications
BACKGROUND/AIM: We previously identified that promoter DNA methylation of cysteine dioxygenase type 1 (CDO1) and homeobox only protein homeobox (HOPX) were both cancer specific, and have a clinical potential as prognostic biomarkers in breast cancer (BC). The present study compared the differential prognostic relevance of methylation status of the CDO1 and HOPX genes in BC.
MATERIALS AND METHODS: Methylation levels (TaqMethVs) were quantified in 7 BC cell lines and 133 BC patients by TaqMan methylation-specific PCR and functional traits were explored for CDO1.
RESULTS: TaqMethVs were associated between CDO1 and HOPX (r
CONCLUSION: CDO1 is a definite tumor suppressor gene, while its prognostic relevance was more than expected in the context of its functional relevance.
Related: MKI67

Atiya HI, Dvorkin-Gheva A, Hassell J, et al.
Intraductal Adaptation of the 4T1 Mouse Model of Breast Cancer Reveals Effects of the Epithelial Microenvironment on Tumor Progression and Metastasis.
Anticancer Res. 2019; 39(5):2277-2287 [PubMed] Related Publications
BACKGROUND: Low success rates in oncology drug development are prompting re-evaluation of preclinical models, including orthotopic tumor engraftment. In breast cancer models, tumor cells are typically injected into mouse mammary fat pads (MFP). However, this approach bypasses the epithelial microenvironment, potentially altering tumor properties in ways that affect translational application.
MATERIALS AND METHODS: Tumors were generated by mammary intraductal (MIND) engraftment of 4T1 carcinoma cells. Growth, histopathology, and molecular features were quantified.
RESULTS: Despite growth similar to that of 4T1 MFP tumors, 4T1 MIND tumors exhibit distinct histopathology and increased metastasis. Furthermore, >6,000 transcripts were found to be uniquely up-regulated in 4T1 MIND tumor cells, including genes that drive several cancer hallmarks, in addition to two known therapeutic targets that were not up-regulated in 4T1 MFP tumor cells.
CONCLUSION: Engraftment into the epithelial microenvironment generates tumors that more closely recapitulate the complexity of malignancy, suggesting that intraductal adaptation of orthotopic mammary models may be an important step towards improving outcomes in preclinical drug screening and development.
Related: Angiogenesis and Cancer

Nikolopoulou A, Galli-Vareia I, Stravodimou A, et al.
[New therapeutic strategies in advanced stage breast and tubo-ovarian cancers].
Rev Med Suisse. 2019; 15(651):1027-1031 [PubMed] Related Publications
New targeted therapies modify therapeutic strategies for advanced stage breast and tubo-ovarian cancers. Chemotherapy and endocrine therapy remain the cornerstones of breast cancer treatment. Inhibitors of CDK4/6, mTOR and PI3K are associated with endocrine therapy to increase its effectiveness. PARP inhibitors outperform chemotherapy in BRCA1/2 mutation carriers. Immunotherapy integrates into the treatment of triple-negative cancers with very promising results. For tubo-ovarian cancers, the concept of « platinum-sensitive » has been tempered since the arrival of antiangiogenic treatment and PARP inhibitors that prolong the disease control not only in patients with BRCA1/2 mutation, but also in others.
Related: BRCA1 BRCA2 Ovarian Cancer

Liu L, Kuang Y, Yang H, Chen Y
An amplification strategy using DNA-Peptide dendrimer probe and mass spectrometry for sensitive MicroRNA detection in breast cancer.
Anal Chim Acta. 2019; 1069:73-81 [PubMed] Related Publications
MicroRNAs (miRNAs) are emerging as novel biomarkers for diagnosis and treatment of various cancers, including breast cancer. Because the value of biomarkers primarily depends on whether they are quantifiable, great effort has been taken to develop assays for sensitive and accurate quantification of miRNAs. However, most of current assays have high nonspecific amplification effect, which limits quantification accuracy. In this study, we circumvented copying of nucleic acid sequence and developed a signal amplification strategy based on a novel DNA-peptide dendrimer (DPD) probe coupled with mass spectrometry. The DPD probe RP8-MAP4-DNA contained three functional domains, including substrate peptides containing eight reporter peptides and tryptic cleavage sites, peptide dendrimer scaffold and DNA complementary to target miRNA. The probe was first hybridized with the target miRNA (i.e., miR-21) that was biotinylated and attached to streptavidin agarose in advance. After trypsin digestion, the reporter peptide was liberated and quantified using LC-MS/MS. The signal intensity was approximately 8 fold greater than that without signal amplification. Finally, the developed assay was applied for the quantitative analysis of miR-21 in 3 human breast cell lines and 102 matched pairs of breast tissue samples. The miR-21 expression in tissue was also evaluated depend on histopathological features, molecular subtypes and prognosis of breast cancer. The result demonstrated that combination of DPD probe and mass spectrometry is a promising strategy for quantification of miRNAs and illustration of their biomarker potential, especially those at low abundance.
Related: MicroRNAs

Contents

Overview
Mutated Genes and Abnormal Protein Expression
Latest Publications
Found this page useful?

Disclaimer: This site is for educational purposes only; it can not be used in diagnosis or treatment.

Cite this page: Cotterill SJ. Breast Cancer, Cancer Genetics Web: http://www.cancer-genetics.org/X0401.htm Accessed:

Creative Commons License
This page in Cancer Genetics Web by Simon Cotterill is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Note: content of abstracts copyright of respective publishers - seek permission where appropriate.

 [Home]    Page last revised: 29 August, 2019     Cancer Genetics Web, Established 1999